Author Index For Volume 32

Note: There are 3 Supplements (21, 22, and 23) in Volume 32, each starting with page S-1.

Aarau K (abst) 432
Abboud OI (abst) 608
Abdel Magid T (abst) 609
Abdel Rahim F (abst) 608
Abdel Rahman ME (abst) 604
Abdel-Maguid AE (abst) 607
Abdel-Rahman Y (abst) 605
Abdel-Salam E (abst) 607
Abe H *See* Fujii M S-153
Abe K *See* Itoh S 493
Abou Raya S (abst) 604
Abou Zeid M (abst) 604
Abouzeid M (abst) 605, 607, 608
Abramow M, Beauwens R, Cogan E: Cellular events in vasopressin action s-56
Abuzaid H (abst) 606
Abuzaid M (abst) 607
Ada WR *See* Sexton PM 862
Addse S (abst) 609
Adelberg EA *See* Aronson PS S-150
Adler S *See* Johnson RJ 342
Agodoa LYC, Mannik M: Removal of subepithelial immune complexes with excess unaltered or cationic antigen 13
Agoury D (abst) 605
Aguado S (abst) 616
Ahijado F (abst) 627
Ajzen H *See* Barros EJG 19
Akano N *See* Takemura T 102
Akano N *See* Yoshioka K 284
Alaupovic P *See* Attman P-O 368
Alawqati Q, Ausiello DA, Bernstein KE, Granner DK, Palade G, Bacallao R, Daniel TO, Brown D, Masur SK, Schwartz GJ, Rennke HG: Dicussion: Russell, Mutations in the LDL receptor S-162
Alcázar JM (abst) 614
Aldridge C *See* Fleming SJ 267
Aldridge RN *See* Fleming SJ 267
Alferink THR (abst) 775
Alfrey AC *See* Ittel TH 821
Alhene0Gelas F *See* Mounier F 684
Aljama P (abst) 620
Allede MT (abst) 622
Allende MT (abst) 629
Alonso de Caso P (abst) 616
Alper SL *See* Andreoli TE S-141
Alper SL *See* Rector FC S-181
Alper SL *See* Giebisch GH S-51
Alper SL *See* Handler JS S-94
Alper SL, Kopito RR, Lodish HF: A molecular biological approach to the study of anion transport . S-117
Alsina J (abst) 612, 614
Altmann P, Butter KC, Plowman D, Chaput de Saintonge DM, Cunningham J, Marsh FP: Residual renal function in hemodialysis patients may protect against hyperaluminemia 710
Alvarez de Lara MA (abst) 621
Alvarez Grande J (abst) 616
Alverez Grande J (abst) 616
Amado JA (abst) 619
Amenabar J (abst) 626
Anaya F (abst) 627
Anderson S *See* Voelker JR 572
Ando A *See* Fujii M S-153
Ando Y *See* Inoue M 198
Andreoli TE, Epstein FH, Warnock DG, Murer H, Birnbaumer L, Alper SL, Rennke HG, Dousa TP, Dirks JH, Guggino WB, Reeves WB: Discussion: Haas and Forbush III: Na, K, Cl-cotransport system S-141
Andrés A (abst) 614
Andreu J (abst) 617
Andreucci VE *See* Conte G 721
Andreucci VE *See* Cianciaruso B S-109
Andrews PM, Bates SB: Dietary protein prior to renal ischemia and postischemic kidney function S-76
Antonio P (abst) 610
Aoyagi K, Nagase S, Narita M, Tojo S: Role of active oxygen on methylguanidine synthesis in isolated rate hepatocytes S-229
Aranda P (abst) 625
Aranzabal J (abst) 626
Arcas R (abst) 625
Ardaillou R *See* Sraer, J 62
Argelagues E (abst) 611
Argiles A, Mourad G, Basset N, Axelrud-Cavadore C, Haiech J, Mion C, Cavadore JC, Demaille JG: Acute adaptative changes to unilateral nephrectomy in humans 714
Arias D (abst) 629
Arias M (abst) 619, 621
Arisz L (abst) 775
Arnold PE *See* Schrier RW 313
Arnold WC, Hill DE, Boughter M: Relationship of nutritional status to erythrocyte insulin receptors in adults and children with uremia S-202
Aronson PS, Fine LG, Ives HE, Berl T, Warnock DG, Skorecki CL, Ausiello DA, Adelberg EA, Daniel TO, Dousa TP, Bacallao R, Igarashi P, Weinman EJ: Discussion: Pouysségur et al, Genetic approach to the $Na^{pr}+H^{pr}+$ antiporter S-150
Arribas JM (abst) 622
Arrizabalaga P (abst) 621, 622
Arslan G (abst) 604
Atkins RC *See* Saito T 691
Attman P-O, Alaupovic P, Gustafson A: Serum apolipoprotein profile of patients with chronic renal failure 368
Aubia J (abst) 610, 611, 612, 613, 617, 618
Ausiello DA *See* Aronson PS S-150
Ausiello DA *See* Alawqati Q S-162
Ausiello DA *See* Fanestil DD S-196
Ausiello DA *See* Jamison RL S-208
Ausiello DA *See* Stein JH S-8
Ausiello DA, Verkman AS, Skorecki KL: Vasopressin-sensitive adenylate cyclase: Subunit

interactions assessed by target analysis and computer modelling. . . . S-43
Avner ED *See* Ellis D 464
Axelrod M *See* Scharschmidt LA 700
Axelrud-Cavadore C *See* Argiles A. . . . 714
Aybasti N (abst). . . . 604
Ayed Kh (abst). . . . 606
Aziz A (abst) 605
Baamonde C (abst). . . . 620
Bacallao R *See* Warnock DG. . . . S-129
Bacallao R *See* Aronson PS. . . . S-150
Bacallao R *See* Alawqati Q S-162
Bacallao R *See* Rector FC. . . . S-181
Baker LRI *See* Fleming SJ 267
Baker P *See* Johnson RJ 342
Balaguer G (abst) 615, 622
Ballarin JA (abst). . . . 619
Ballerman BJ *See* Stein JH S-8
Bankir L *See* Bouby N S-57
Bannister KM, Ulich TR, Wilson CB: Induction, characterization, and cell transfer of autoimmune tubulointersitial nephritis 642
Barbry P *See* Frelin C 785
Barceló P (abst) 619
Barcia F (abst) 616
Barghash N (abst) 604
Bariety J *See* Pelletier L 227
Barradas MA *See* Grace AA 889
Barrera M (abst). . . . 620
Barrientos A (abst). . . . 613, 615
Barrio V (abst). . . . 628
Barros EJG, Boim MA, Ajzen H, Ramos OL, Schor N: Glomerular hemodynamics and hormonal participation on cyclosporine nephrotoxicity. . . . 19
Barsoum M (abst) 605
Barsoum R (abst) 604, 605, 606, 607, 608
Bartolomé J (abst) 614
Basgen JM *See* Bilous RW 930
Basile C *See* Teo KK 399
Basset N *See* Argiles A 714
Basta M (abst) 605
Bates SB *See* Andrews PM S-76
Bear RA *See* West ML 579
Beasley D, Oza NB, Levinsky NG: Micropuncture localization of kallikrein secretion in the rat nephron 26
Beauwens R *See* Abramow M s-56
Becker GJ *See* El-Khatib MT 261
Befus D (abst) 605
Bellow I (abst) 614
Ben Ayed H (abst). . . . 606, 608
Ben Maiz H (abst) 606, 608
Ben Moussa F (abst) 606, 608
Benali M (abst). . . . 605
Benali S (abst) 605
Benarabia S (abst) 608
Benito P (abst). . . . 620
Benmiloud M (abst). . . . 605
Bennett WM *See* Elzinga LW 884
Bens M *See* Sraer, J 62
Benveniste J (abst). . . . 614
Benveniste J *See* Pirotzky E 233
Berden JHM (abst). . . . 776
Beretta-Piccoli C (abst) 432
Berger P *See* Scharschmidt LA. . . . 700
Berian JM (abst). . . . 625
Berl T *See* Aronson PS S-150
Berl T *See* Schrier RW S-38
Bernstein H, Yang VC, Lund D, Randhawa M, Harmon W, Langer R: Extracorporeal enzymatic heparin removal: Use in a sheep dialysis model. . . . 452
Bernstein KE *See* Warnock DG S-129
Bernstein KE *See* Alawqati Q S-162
Bernstein KE *See* Stein JH S-8
Bernstein KE *See* Handler JS S-94
Berthous F (abst). . . . 606
Berthoux FC (abst) 606
Berthoux P (abst). . . . 606
Besarab A, Caro J, Jarrell BE, Francos G, Ersley AJ: Dynamics of erythropoiesis following renal transplantation 526
Better OS: Impaired fluid and electrolyte balance in hot climates S-97
Beukers JJB, van der Wal A, Hoedemaeker PJ, Weening JJ: Converting enzyme inhibition and progressive glomerulosclerosis in the rat. . . . 794
Bia M *See* Castellino P 877
Bianchi L (abst) 431
Bichsel G (abst) 432
Bidault J *See* Pirotzky E 233
Bidiville J *See* Biollaz J 537
Bijman J: Transport processes in the eccrine sweat gland S-109
Bilgin N (abst) 604
Bilo HJG (abst) 775
Bilous RW, Mauer SM, Basgen JM, Steffes MW: Estimation of mean glomerular volume in patients with insulin-dependent diabetes mellitus (Technical Note). . . . 930
Binder BR *See* Speiser W 280
Binswanger U (abst) 432
Biollaz J, Bidiville J, Diézi J, Waeber B, Nussberger J, Brunner-Ferber F, Gomez HJ, Brunner HR: Site of the action of a synthetic atrial natriuretic peptide evaluated in humans. . . . 537
Birnbaumer L *See* Andreoli TE. . . . S-141
Birnbaumer L *See* Giebisch GH S-51
Birnbaumer L *See* Klahr S S-77
Birnbaumer L *See* Stein JH. . . . S-8
Birnbaumer L, Codina J, Mattera R, Yatani A, Scherer N, Toro M-J, Brown AM: Signal transduction by G proteins S-14
Blanco J (abst). . . . 615
Blantz RC, Gabbai F, Gushwa LC, Wilson CB: The influence of concomitant experimental hypertension and glomerulonephritis 652
Blasco R (abst). . . . 628
Blumberg A (abst) 432
Boer WH (abst) 776, 777
Boer WH, Koomans HA, Mees EJD: Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man 376
Boim MA *See* Barros EJG 19
Bolton WK, Innes DJ Jr, Sturgill BC, Kaiser DL: T-cells and macrophages in rapidly progressive glomerulonephritis: Clinicopathologic correlations. . . . 869
Bommer J *See* Merke J 350
Bonal J (abst). . . . 613
Bondia A (abst) 618
Bonet J (abst). . . . 613

Bonjour JP (abst) 435
Borkan S, Northrup TE, Cohen JJ, Garella S: Renal response to metabolic alkalosis induced by isovolemic hemofiltration in the dog 322
Bosch RJ (abst) 628
Botella J (abst) 613
Botey A (abst) 624
Bouby N, Trinh-Trang-Tan M-M, Kriz W, Bankir L: Possible role of the thick ascending limb and of the urine concentrating mechanism in the protein-induced increase in GFR and kidney mass.. S-57
Boudet J *See* Pirotzky E 233
Boughter M *See* Arnold WC S-202
Boukari M (abst) 605
Branch RA *See* Heidemann HTH 488
Brater DC *See* Voelker JR 572
Breedveld FC (abst) 777
Breidenbach Th *See* Rawer P S-149
Brenner BM, Schrier RW, Striker GE, Brown D, Rabkin R, Jamison RL, Hammerman MR, Seifter JL, Daniel TO, Skorecki CL, Fine LG: Discussion: Roth et al, Hormone receptor interactions S-61
Breto M (abst) 617
Breuning MH (abst) 772
Brill JE *See* Salusky IB 89
Briner V (abst) 431
Brinster RL *See* MacKay K 827
Brodde O-E *See* Daul AE 728
Brown AM *See* Birnbaumer L S-14
Brown D *See* Warnock DG S-129
Brown D *See* Alawqati Q S-162
Brown D *See* Jamison RL S-208
Brown D *See* Brenner BM S-61
Brown J *See* Jamison RL S-208
Broyer M *See* Laouari D S-186
Broyer M *See* Kleinknecht C S-62
Brühlmann P (abst) 438
Bruijn JA (abst) 774
Brukman J, Wiggins RC: Procoagulant activity in kidneys of normal and bacterial lipopolysaccharide-treated rabbits 31
Brunner FP (abst) 431
Brunner HR *See* Biollaz J 537
Brunner S (abst) 431
Brunner W (abst) 438
Brunner-Ferber F *See* Biollaz J 537
Buddington B *See* Ittel TH 821
Burckhardt P (abst) 434
Burdiel LG (abst) 620
Burette A *See* Dratwa M S-32
Burg MB, Schultz SG, Daniel TO, McDonough A, Edelman I, Rossier B, Forbush B III: Discussion: Fambrough et al, Sodium pump regulation S-113
Burger HR (abst) 432, 433
Bürgi W (abst) 432
Burke TJ *See* Schrier RW 313
Burtin C *See* Pirotzky E 233
Butter KC *See* Altmann P 710
Byrd R *See* Faubert PF 472
Cabello M (abst) 625
Cabezuelo J (abst) 617
Cabrera L (abst) 627
Cabrero Gonzólez J (abst) 627
Calero F (abst) 619
Calvete H (abst) 627
Calvo A (abst) 620
Calvo C (abst) 610
Campanacci L *See* Guarnieri G S-116
Campistol JM (abst) 623, 624
Camps J (abst) 619
Candiano G *See* Ghiggeri GM 69, 547
Canga E (abst) 621
Cannata JB (abst) 622, 629
Cannon JK *See* Olbricht CJ 354
Cano F (abst) 612
Cano N, Fernandez JP, Lacombe P, Lankester M, Pascal S, Defayolle M, Labastie J, Saingra S: Statistical selection of nutritional parameters in hemodialyzed patients S-178
Cantarell MC (abst) 619
Canton AD *See* Conte G 721
Capasso G, De Santo NG, Kinne R: Thyroid hormones and renal transport: Cellular and biochemical aspects (Editorial Review) 43
Capdevila L (abst) 617
Capistol JM (abst) 624
Caralps A (abst) 611, 613
Carlson RW *See* Desai TK S-225
Caro J *See* Besarab A 526
Caron MG *See* Dohlman HG S-2
Carone FA *See* Grantham JJ 187
Carr ME *See* Elzinga LW 884
Carratalá J (abst) 614
Carrera M (abst) 612
Carreras M (abst) 621
Carretero OA *See* Ura N 507
Cartwright-Brown D *See* Voelker JR 572
Casado S (abst) 628
Casanova D (abst) 619
Cases A (abst) 623, 624
Castelao AM (abst) 612
Castellino P, Bia M, DeFronzo RA: Metabolic response to exercise in dialysis patients 877
Castellino P, Hunt W, DeFronzo RA: Regulation of renal hemodynamics by plasma amino acid and hormone concentrations S-15
Castillo D (abst) 620
Castillo R (abst) 623
Castro AM (abst) 627
Castro JM (abst) 616
Castro M (abst) 620
Catalano C *See* Maggiore Q 908
Cats A (abst) 777
Cattell WR *See* Fleming SJ 267
Cavadore JC *See* Argiles A 714
Caverzasio J (abst) 435
Caycho C (abst) 629
Chafik NR (abst) 607
Chantler C *See* Greene SA 896
Chantler C *See* Mak RHK S-206
Chaput de Saintonge DM *See* Altmann P 710
Charlier L *See* Dratwa M S-32
Chauveau Ph *See* Jungers P S-67
Chavers B *See* Ellis EN 736
Chen A *See* Rifai A 838
Chine M (abst) 613
Chou S-Y *See* Faubert PF 472
Christen R (abst) 433
Cianciaruso B, Saccà L, Terracciano V, Marcuccio F, Orofino G, Petrone A, Andreucci VE, Kopple JD:

Insulin metabolism in acute renal failure S-109
Cianciaruso B *See* Conte G 721
Ciancioni C *See* Jungers P S-67
Ciardi MR *See* Ghiggeri GM 69
Clark AS *See* Mitch WE S-104
Clemens TL (abst) 434
Clement J (abst) 603, 774
Coburn JW *See* Salusky IB 89
Coburn JW *See* Hercz G S-215
Codina J *See* Birnbaumer L S-14
Coe FL *See* Kristensen C 749
Cogan E *See* Abramow M s-56
Cohen JJ *See* Borkan S 322
Cohen Tervaert JW (abst) 778
Collart F *See* Dratwa M S-32
Collaud TH (abst) 433
Company X (abst) 621
Conde J (abst) 622
Conte G, Canton AD, Terribile M, Cianciaruso B, Di Minno G, Pannain M, Russo D, Andreucci VE: Renal handling of urea in subjects with persistent azotemia and normal renal function 721
Copeland KR, Yatscoff RW, Thliveris JA, Mehta A, Penner B: Non-enzymatic glycation and altered renal structure and function in the diabetic rat 664
Corominas A (abst) 613
Coronel F (abst) 613, 615
Corry DB, Lee DBN, Tuck ML: A kinetic study of cation transport in erythrocytes from uremic patients 256
Corsi M *See* Guarnieri G S-116
Corwin HL *See* Schwartz MM 274
Cosmes PG (abst) 627
Cotorruelo JG (abst) 619, 621
Couser WG *See* Johnson RJ 342
Crapesi L *See* Guarnieri G S-116
Crowe MJ *See* Ledingham JGG S-90
Cruceyra A (abst) 615
Cruz JM (abst) 610, 617
Cruz PA (abst) 617
Cuesta MV (abst) 618
Cuevas X (abst) 610, 611, 612, 617, 618
Cuniberti C *See* Ghiggeri GM 69
Cunningham J *See* Altmann P 710
Cunningham JT *See* Johnson AK S-35
Cuxart M (abst) 613
Daha MR (abst) 772, 774, 777
Dakroury A (abst) 609
Dakroury AM (abst) 604
Dalmeida W *See* Rouse D 845
Dalton RN *See* Greene SA 896
Dambacher MA (abst) 431
Dandona P *See* Grace AA 889
Daniel TO *See* Burg MB S-113
Daniel TO *See* Aronson PS S-150
Daniel TO *See* Alawqati Q S-162
Daniel TO *See* Rector FC S-181
Daniel TO *See* Brenner BM S-61
Danielson BG (abst) 608
Daugirdas JT, Nawab ZM, Jain S, Klok M: Acetate relaxation of isolated vascular smooth muscle 39
Daul AE, Wang XL, Michel MC, Brodde O-E: Arterial hypotension in chronic hemodialyzed patients 728
Davidson WD *See* Laidlaw SA S-191
Davis TA *See* Heifets M 815
De Arriba G (abst) 627, 628
de Francisco ALM (abst) 621, 629
de Francisco AM (abst) 619, 620
de Heer E (abst) 774
de Jong PE (abst) 773
de Jong PE *See* Heeg JE 78
de Jong RBJ (abst) 775
De Keijzer MH (abst) 772
De la Calle O (abst) 617
de la Piedra C (abst) 629
de Nicolas R (abst) 627, 628
de Nobel E (abst) 776
De Santo NG *See* Capasso G 443
de Torrente A (abst) 437
De Vernejoul M-C *See* London GM 900
de Zeeuw D (abst) 773
de Zeeuw D *See* Heeg JE 78
Deelder A (abst) 605
Defayolle M *See* Cano N S-178
Deferrari G *See* Tizianello A S-181
DeFronzo RA *See* Castellino P 877
DeFronzo RA *See* Castellino P S-15
del Arco C (abst) 619
del Barrio E (abst) 627
Del Bianco MA *See* Guarnieri G S-116
del Pozo C (abst) 613, 615
del Rio G (abst) 619
Delfino G *See* Ghiggeri GM 69
Deltenre M *See* Dratwa M S-32
Demaille JG *See* Argiles A 714
Deris Y *See* Mounier F 684
Desai TK, Carlson RW, Geheb MA: Parathyroid-vitamin D axis in critically ill patients with unexplained hypocalcemia S-225
Descoeudres C (abst) 434
Deuber HJ (abst) 433, 436
Dhaene M, Sabot J-P, Philippart Y, Doutrelepont J-M, Vanherweghem J-L: Effects of acute protein loads to different sources on glomerular filtration rate S-25
Di Minno G *See* Conte G 721
Diamond JR, Karnovsky MJ: Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation 671
Diaz de Greñu MC (abst) 622, 629
Diaz Flores L (abst) 623
Diaz L (abst) 623
Dieguez A (abst) 616
Diez J (abst) 625, 626
Diez JC (abst) 615
Diezi J (abst) 432, 434
Diézi J *See* Biollaz J 537
Díez-Tejeiro J (abst) 626
Ding G *See* Hays RM S-51
Dirks JH *See* Andreoli TE S-141
Dodu C *See* Laouari D S-186
Dodu C *See* Kleinknecht C S-62
Dohlman HG, Caron MG, Lefkowitz RJ: Structure and function of the $_{fr}$2-adrenergic receptor homology with rhodopsin S-2
Dominguez MJ (abst) 615
Donker AJM (abst) 775, 778
Donoso VS *See* Grantham JJ 187
Dorhout Mees EJ (abst) 773, 774, 776
Dornfeld LP, Maxwell MH, Waks A, Tuck M: Mechanisms of hypertension in obesity S-254
Dousa TP *See* Andreoli TE S-141

Dousa TP *See* Aronson PS. S-150
Dousa TP *See* Rector FC. S-181
Dousa TP *See* Jamison RL. S-208
Dousa TP *See* Giebisch GH. S-51
Dousa TP *See* Stein JH S-8
Dousa TP *See* Handler JS S-94
Doutrelepont J-M *See* Dhaene M S-25
Dratwa M, Burette A, Van Gossum M, Collart F, Wens R, Charlier L, Tielemans C, Deltenre M: No rise in glomerular filtration rate after protein loading in cirrhotics S-32
Drickamer K: Membrane receptors that mediate glycoportein endocytosis: Structure and biosynthesis S-167
Drif M (abst). 604, 605
Drüeke T *See* Merke J. 204
Druet P *See* Pelletier L 227
Dubach UC (abst) 435
Dudek MA *See* Wesson DE 238
Dunn MJ *See* Patrono C 1
Dunn MJ *See* Rahman MA S-40
Dunn SR *See* Lele PS S-159
Duursma SA (abst). 777
Ecija JL (abst) 611
Edelman I *See* Burg MB S-113
Edelman I *See* Handler JS. S-94
Egido J (abst) 627, 628
Egli F (abst) 438
El *See* Feinstein S-167
El Matri A (abst) 606, 608
El Nahas AM, Zoob SN, Evans DJ, Rees AJ: Chronic renal failure after nephrotoxic nephritis in rats: Contributions to progression 173
El Younsi F (abst) 608
El-Badry A (abst). 605
El-Bahay AM (abst). 604
El-Baz M (abst) 604
El-Baz TZ (abst) 609
El-Baz Z (abst). 609
El-Dein ABS (abst) 603
El-Ghadban H (abst) 607
El-Ghonaimy E (abst) 606, 607
El-Ghonaimy El (abst). 607
El-Ghonaimy E (abst) 608
El-Ghonemy E (abst). 607
Elghonemy H (abst). 604
El-Haddad S (abst). 605
El-Helaly AAM (abst) 606
El-Hilaly I (abst) 608
Elkhashab O (abst). 604, 606, 607
El-Khatib MT, Becker GJ, Kincaid-Smith PS: Morphometric aspects of reflux nephropathy 261
Ellis D, Sothi TD, Avner ED: Glucocorticoids modulate renal glucocorticoid receptors and Na-K ATPase activity 464
Ellis EN, Steffes MW, Chavers B, Mauer SM: Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus. 736
Ellis HA (abst). 620
El-Sersawy G (abst). 605
El-Sherif A (abst). 605
Elving LD (abst) 776
Elzinga LW, Golper TA, Rashad AL, Carr ME, Bennett WM: Trimethoprim-sulfamethoxazole in cyst fluid from autosomal dominant polycystic kidneys 884
Enia G *See* Maggiore Q. 908
Ensminger A *See* Seyffart G S-174
Epstein FH *See* Andreoli TE. S-141
Erdös EG *See* Ura N. 507
Eriksen EF, Richelsen B, Gesser BP, Jacobsen NO, Stengaard-Pedersen K: Prostaglandin-$E_{tr}2$ receptors in the rat kidney: Biochemical characterization and localization 181
Errasti P (abst). 625, 626
Ersley AJ *See* Besarab A 526
Escobedo JM (abst) 622
Escolá G (abst). 623
Escolar G (abst). 624
Escuín F (abst). 612, 617, 622
Eshmawy M (abst). 607
Esparza N (abst) 626
Esteller E (abst). 611
Evan AP *See* Grantham JJ 187
Evan AP *See* Gardner KD. 329
Evans DJ *See* El Nahas AM. 173
Exton JH: Calcium signalling in cells—molecular mechanisms. S-68
Ezzat E (abst) 605
Fabiani F *See* London GM 900
Fabris A *See* Maschio G S-49
Fambrough DM, Wolitzky BA, Tamkun MM, Takeyasu K: Regulation of the sodium pump in excitable cells S-97
Famira K III (abst) 436
Fanconi A (abst) 438
Fanestil DD, Rector FC Jr, Stone DK, Rabkin R, McDonough A, Ausiello DA, Warnock DG, Handler JS, Masur SK: Discussion: Mellman, Molecular sorting during endocytosis S-196
Farghal SI (abst) 606
Farquhar MG *See* Warnock DG S-129
Faubert PF, Chou S-Y, Porush JG, Byrd R: Regulation of papillary plasma flow by angiotensin II. 472
Fdez Vega F (abst) 616
Fdez-Vega F (abst) 616
Fehr S *See* Schmale H. S-8
Feinstein, EI: Nutritional hemodialysis. S-167
Félez J (abst) 619
Fernandez JP *See* Cano N S-178
Fernández Menéndez MJ (abst) 622
Fernàndez-Soto I (abst). 622
Figuereo A (abst). 621
Fine LG *See* Aronson PS. S-150
Fine LG *See* Brenner BM S-61
Fine LG: The role of nutrition in hypertrophy of renal tissue S-2
Fine RN *See* Salusky IB 89
Finn WF, Hak LJ, Grossman SH: Protective effect of prostacyclin on postischemic acute renal failure in the rat 479
Fleming SJ, Wilkinson JS, Greenwood RN, Aldridge RN, Aldridge C, Baker LRI, Cattell WR: Effect of dialysate composition on intercompartmental fluid shift 267
Fleuren GJ (abst) 774
Foidart JM (abst) 774
Fombellida JC (abst) 615
Fontán MP (abst). 619
Fontcuberta J (abst). 619
Forbush B III *See* Burg MB S-113

Forbush B III *See* Haas M. S-134
Forbush B III *See* Giebisch GH S-51
Forsling ML *See* Ledingham JGG S-90
Förstner-Wanner S *See* Wanner C S-132
Fort J (abst) 619
Fox JE *See* Mistry CD S-210
Frampton G (abst) 603
Franchi A *See* Pouysségur J S-144
Francis M (abst) 605, 607, 608
Franco A (abst) 627
Francos G *See* Besarab A 526
Franki N *See* Hays RM S-51
Franz HE *See* Kohse KP S-128
Frederik PFM *See* Tiebosch ATMG 112
Frelin C, Vigne P, Barbry P, Lazdunski M: Molecular properties of amiloride action and of its Na^{pr}+ transporting targets (Editorial Review) 85
Freuler PV *See* Labonia WD 754
Frey FJ (abst) 433, 434
Frick A *See* Jahn HA S-197
Fries JWU, Rumpelt H-J, Thoenes W: Alterations of glomerular podocytic processes in immunologically mediated glomerular disorders 742
Frömter E: Cellular handling of water S-2
Frutos MA (abst) 625
Fujii M, Ando A, Mikami H, Okada A, Imai E, Kokuba Y, Yamauchi A, Orita Y, Kamad T, Abe H: Effect of the restriction of nitrogen intake on muscle protein synthesis in experimental uremic rats. S-153
Fürst P *See* Kohse KP S-128
Fürst P *See* Wanner C S-132
Gabbai F *See* Blantz RC 652
Gable J III *See* Metcoff J S-136
Gabreëls F (abst) 776
Gagnon RF *See* Gallimore B 678
Gaillard CA (abst) 774
Gainza J (abst) 615, 626
Galal S (abst) 604
Galceran M *See* Pelletier L 227
Galceran T, Martin KJ, Morrissey JJ, Slatopolsky E: Role of 1, 25-dihydroxyvitamin D on the skeletal rsistance to parathyroid hormone. 801
Galla JH *See* Sanders PW 851
Gallego E (abst) 615
Gallimore B, Gagnon RF, Richards GK: Response to intraperitoneal *Staphylococcus epidermidis* challenge in renal failure mice 678
Gammaro L *See* Maschio G. S-49
Ganten D *See* Mann JFE S-27
Garcés L (abst) 622
García C (abst) 620
Garcia de la Peña E (abst) 629
Garcia Fernandez F (abst) 626
García Hoyo R (abst) 627, 628
Garcia J (abst) 610, 617
García M (abst) 621
García Robles R (abst) 614
García-Bragado F (abst) 612
Gardner KD, Reed WP, Evan AP, Zedalis J, Hylarides MD, Leon AA: Endotoxin provocation of experimental renal cystic disease 329
Gardner KD Jr *See* Grantham JJ 187
Garella S *See* Borkan S 322
Garibotto G *See* Tizianello A S-181
Garrido M (abst) 624
Gautier E (abst) 437
Gayá A (abst) 617
Gaya J (abst) 620, 624
Geheb MA *See* Desai TK. S-225
Gerber B (abst) 434
Gerkens JF *See* Heidemann HTH. 488
Gesser BP *See* Eriksen EF 181
Ghezzi PM (abst) 613
Ghiggeri GM, Ginevri F, Candiano G, Oleggini R, Perfumo F, Queirolo C, Gusmano R: Characterization of cationic albumin in minimal change nephropathy 547
Ghiggeri GM, Candiano G, Ginevri F, Gusmano R, Ciardi MR, Perfumo F, Delfino G, Cuniberti C, Queirolo C: Renal selectivity properties towards endogenous albumin in minimal change nephropathy 69
Ghonaimy E (abst) 605
Ghoneim M (abst) 603
Ghoneim MA (abst) 603
Ghoneim M (abst) 605
Gibbons NB *See* Scharschmidt LA. 700
Giebisch GH, Verkman A, Skorecki CL, Jacobson HR, Lefkowitz RJ, Birnbaumer L, Roth J, Forbush B III, Dousa TP, Alper SL, Masur SK: Discussion: Ausiello et al, Subunit interactions. S-51
Gil-Cepeda F (abst) 625
Gilli G *See* Salusky IB. 89
Gil-Vernet S (abst) 612
Gimenez A (abst) 610
Gimenez M (abst) 617
Gimenez MI *See* Labonia WD 754
Ginevri F *See* Ghiggeri GM. 69, 547
Glasgow EF *See* Saito T 691
Gloor F (abst) 438
Gmür J (abst) 433
Gnädinger MP (abst) 434, 436
Gnädinger MP *See* Saxenhofer H 554
Gnaedinger MP (abst) 435
Goetz FC (abst) 619
Gokal R *See* Mistry CD S-210
Gokce O (abst) 604
Gold R *See* Salusky IB 89
Goldschmeding R (abst) 779
Goldstein MB *See* West ML 579
Goligorsky MS *See* Jamison RL S-208
Golper TA *See* Elzinga LW. 884
Gomez E (abst) 616
Gomez HJ *See* Biollaz J 537
Gomez J (abst) 620
Gomez R (abst) 624
Gomez-Ullate P (abst) 615
González E (abst) 627
Gonzalez F (abst) 620
Gonzalez FM (abst) 620
Gonzalez M (abst) 621
Gonzalez-Molina M (abst) 625
Gonzalo A (abst) 610, 611, 612
Goodman WG *See* Salusky IB 89
Götz R *See* Heidbreder E S-221
Gouget B *See* Kleinknecht C. S-62
Gouyon JB (abst) 437
Grace AA, Barradas MA, Mikhailidis DP, Jeremy JY, Moorhead JF, Sweny P, Dandona P: Cyclosporine A enhances platelet aggregation. 889

Granner DK *See* Jacobson HR S-1
Granner DK *See* Alawqati Q S-162
Granner DK: The molecular biology of insulin action on protein synthesis S-82
Grant C (abst) 629
Grantham JJ, Donoso VS, Evan AP, Carone FA, Gardner KD Jr: Viscoelastic properties of tubule basement membranes in experimental renal cystic disease 187
Gras-Balaguer X (abst) 614
Graser TA *See* Kohse KP S-128
Greene SA, Dalton RN, Turner C, Haycock GB, Chantler C: Hyperglycemia with and without glycosuria: Effect on inulin and para-amino hippurate clearance 896
Greenwood RN *See* Fleming SJ 267
Grigoras O (abst) 437
Grino JM (abst) 611, 617
Griño MC (abst) 624
Gros F *See* Mounier F 684
Gross P, Ritz E: Introduction S-1
Gross PA, Ketteler M, Hausmann C, Ritz E: The charted and the uncharted waters of hyponatremia . S-67
Grossman SH *See* Finn WF 479
Guarnieri G, Toigo G, Crapesi L, Situlin R, Del Bianco MA, Corsi M, LoGreco P, Paviotti G, Mioni G, Campanacci L: Carnitine metabolism in chronic renal failure S-116
Gubler M-C *See* Mounier F 684
Guelpa G (abst) 433
Guerin AP *See* London GM 900
Guerrero R (abst) 620
Guggino WB *See* Andreoli TE S-141
Guignard JP (abst) 437, 438
Guillain H (abst) 432, 434
Gushwa LC *See* Blantz RC 652
Gusmano R *See* Ghiggeri GM 547
Gusmano R *See* Ghiggeri GM 69
Gustafson A *See* Attman P-O 368
Gutiérrez Millet V (abst) 614
Gutkowska J (abst) 628
Guttmann W *See* Rawer P S-149
Haaijman JJ (abst) 774
Haas M, Forbush B III: Na, K, Cl-cotransport system: Characterization by bumetanide binding and photolabelling S-134
Haberal M (abst) 604
Haiech J *See* Argiles A 714
Hak LJ *See* Finn WF 479
Haller H *See* Klahr S S-77
Hamari N (abst) 608
Hammerman MR *See* Jamison RL S-208
Hammerman MR *See* Brenner BM S-61
Hammerman MR *See* Klahr S S-77
Hancock JR *See* Sanders PW 851
Handler JS *See* Fanestil DD S-196
Handler JS *See* Jamison RL S-208
Handler JS, Bernstein KE, Dousa TP, Edelman I, Masur SK, Pollack AS, Alper SL: Discussion: Granner, Insulin and gene transcription S-94
Hara Y, May RC, Kelly RA, Mitch WE: Acidosis, not azotemia, stimulates branched-chain, amino acid catabolism in uremic rats 808
Harcajo P (abst) 613
Harding GB *See* Ward RA 129
Harmon W *See* Bernstein H 452
Hassabalah A (abst) 607
Hassaballa A (abst) 604, 605, 606, 607, 608
Hassaballa N (abst) 606
Hassaballah N (abst) 603
Hassan AA (abst) 606
Hassar M (abst) 605
Hasslacher C, Ritz E: Effect of control of diabetes mellitus on progression of renal failure S-53
Hausmann C *See* Gross PA S-67
Haycock G *See* Mak RHK S-206
Haycock GB *See* Greene SA 896
Hays RM, Ding G, Franki N: Morphological aspects of the action of ADH S-51
Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Reduction of proteinuria by angiotensin converting enzyme inhibition 78
Heidbreder E *See* Heidland A S-94
Heidbreder E, Götz R, Schafferhans K, Heidland A: Renal and hepatic uptake of biologically active intact parathyroid hormone S-221
Heidemann HTH, Jackson EK, Gerkens JF, Branch RA: Intrarenal hypertonic saline infusions in dogs with thoracic caval constriction 488
Heidland A *See* Kopple JD S-1
Heidland A *See* Schaefer RM S-100
Heidland A *See* Plass R S-113
Heidland A *See* Heidbreder E S-221
Heidland A, Weipert J, Schaefer RM, Heidbreder E, Peter G, Hörl WH: Porteases and other catabolic factors in renal failure S-94
Heifets M *See* Klahr S S-35
Heifets M, Morrissey JJ, Purkerson ML, Morrison AR, Klahr S: Effect of dietary lipids on renal function in rats with subtotal nephrectomy 335
Heifets M, Davis TA, Tegtmeyer E, Klahr S: Exercise training ameliorates progressive renal disease in rats with subtotal nephrectomy 815
Helbing F *See* Merke J 204
Helmy SM (abst) 606
Hené RJ (abst) 773
Hercz G, Coburn JW: Prevention of phosphate retention and hyperphosphatemia in uremia S-215
Hernández I (abst) 614
Hernandez Nieto L (abst) 623
Hernando L (abst) 627, 628
Hernando N (abst) 628
Herrera GA *See* Sanders PW 851
Herrera J (abst) 629
Herrero E (abst) 620
Herreros J (abst) 625
Hess C *See* Saxenhofer H 554
Hess Ch (abst) 435
Hetherington MD *See* Teo KK 399
Heule H (abst) 438
Higashi GI (abst) 607
Hill DE *See* Arnold WC S-202
Hill JM *See* Roth J S-56
Hinglais N *See* Mounier F 684
Hirschberg R, Kopple JD: Role of growth hormone in the amino acid-induced acute rise in renal function in man 382
Hirschberg R, Kopple JD: Effects of growth hormone on GFR and renal plasma flow in man S-21
Hodler J (abst) 436

Hoedemaeker PHJ (abst) 774
Hoedemaeker PJ *See* Beukers JJB 794
Hofbauer KG, Mah SC: Vasopressin antagonists: Present and future S-76
Hogendoorn PCW (abst) 774
Hogewind BL (abst) 772
Hoitsma AJ (abst) 772, 775, 776
Hojman L (abst) 613
Holick MF: Vitamin D and the kidney (Nephrology Forum) 912
Hoppel CL *See* Ricanati ES S-145
Horber FF (abst) 434
Hörl WH *See* Schaefer RM S-100
Hörl WH *See* Plass R S-113
Hörl WH *See* Wanner C S-132
Hörl WH *See* Heidland A S-94
Hortal L (abst) 613, 615
Hruska KA *See* Klahr S S-77
Huarte E (abst) 612, 617, 618, 619
Huber E (abst) 432
Hug C (abst) 438
Hügel U *See* Merke J 204
Hügel U *See* Merke J 350
Huisman RM (abst) 773
Humair L (abst) 437
Hunt W *See* Castellino P S-15
Huser B (abst) 431
Huysmans FTM (abst) 775
Hylarides MD *See* Gardner KD 329
Igarashi P *See* Aronson PS S-150
Iijima K *See* Yoshikawa N 585
Imai E *See* Fujii M S-153
Imai H *See* Rifai A 838
Indart F (abst) 626
Innes DJ Jr *See* Bolton WK 869
Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y: Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients 198
Iseki T *See* Yoshioka K 284
Iskandar IR (abst) 607
Itoh K *See* Inoue M 198
Itoh S, Abe K, Nushiro N, Omata K, Yasujima M, Yoshinaga K: Effect of atrial natriuretic factor on renin release in isolated afferent arterioles 493
Ittel TH, Buddington B, Miller NL, Alfrey AC: Enhanced gastrointestinal absorption of aluminum in uremic rats 821
Ives HE *See* Aronson PS S-150
Ives HE *See* Rector FC S-181
Ives HE *See* Klahr S S-77
Jackson EK *See* Heidemann HTH 488
Jacobsen NO *See* Eriksen EF 181
Jacobson HR *See* Giebisch GH S-51
Jacobson HR, Granner DK, Robinson RR: Introduction . S-1
Jaeger Ph (abst) 434
Jahn HA, Schohn DC, Schmitt RL, Koehl C, Zawislak R, Frick A: Influence of increased plasma ammonium levels on the ratio of plasma to erythrocyte amino acids S-197
Jahn H *See* Saxenhofer H 554
Jahoor F, Wolfe RR: Regulation of protein catabolism .. S-81
Jain S *See* Daugirdas JT 39
Jamison RJ: The renal concentrating mechanism S-43
Jamison RL *See* Rector FC S-181
Jamison RL *See* Brenner BM S-61
Jamison RL, Hammerman MR, Kurokawa K, Handler JS, Stokes JB, Brown D, Schrier RW, Brown J, Ausiello DA, Dousa TP, Masur SK, Goligorsky MS: Discussion: Simons, Membrane traffic in MDCK cells S-208
Janis R *See* Scharschmidt LA 700
Janssen WMT (abst) 773
Jaraba M (abst) 620
Jarrell BE *See* Besarab A 526
Jeekel J (abst) 777
Jeremy JY *See* Grace AA 889
Jilderda JF (abst) 773
Jindal KK *See* West ML 579
Johnson AK *See* Mann JFE S-27
Johnson AK, Cunningham JT: Brain mechanisms and drinking: The role of lamina terminalis-associated systems in extracellular thirst S-35
Johnson RJ, Klebanoff SJ, Ochi RF, Adler S, Baker P, Sparks L, Couser WG: Participation of the myeloperoxidase-$H_{fr}2O_{fr}2$-halide system in immune complex nephritis 342
Joles JA (abst) 776
Jordans JGM (abst) 777
Jungers P, Chauveau Ph, Ployard F, Lebkiri B, Ciancioni C, Man NK: Comparison of ketoacids and low protein diet on advanced chronic renal failure progression S-67
Junor BJR (abst) 629
Kaiser DL *See* Bolton WK 869
Kallenberg CGM (abst) 778
Kamad T *See* Fujii M S-153
Kamel M (abst) 605, 607, 609
Kamm DE, Wu L, Kuchmy BL: Contribution of the urea appearance rate to diuretic-induced azotemia in the rat 47
Kangarloo H *See* Salusky IB 89
Kanwar YS *See* Lelongt B 498
Kappagoda T *See* Teo KK 399
Karamehmetoglu M (abst) 604
Karnovsky MJ *See* Diamond JR 671
Kasinath BS *See* Pugliese F 57
Kawala KS *See* Schwartz MM 274
Kelly RA *See* Hara Y 808
Kelly RA *See* Mitch WE S-104
Kerr DNS (abst) 620
Kesteloot D (abst) 778
Ketteler M *See* Gross PA S-67
Keusch G (abst) 433
Khanna R *See* Mactier RA 165
Khanna R *See* Nolph KD 219
Khashab O (abst) 605, 607
Khater OMR (abst) 604
Kheder A (abst) 608
Kheder MA (abst) 606, 608
Kim JK *See* Schrier RW S-113
Kincaid-Smith PS *See* El-Khatib MT 261
Kinne R *See* Capasso G 443
Kinuthia DMW (abst) 606
Kirchheimer JC *See* Speiser W 280
Klahr S, Purkerson ML, Heifets M: Factors that may retard the progression of renal disease S-35
Klahr S, Schrier RW, Haller H, Stokes JB, Roth J, Skorecki CL, Ives HE, Navar LG, Weinman EJ, Birnbaumer L, Ullrich KJ, Hruska KA,

Hammerman MR: Discussion: Exton, Calcium signalling mechanisms in cells S-77
Klahr S *See* Heifets M..... 335
Klahr S *See* Heifets M..... 815
Klebanoff SJ *See* Johnson RJ 342
Kleinknecht C *See* Laouari D S-186
Kleinknecht C, Laouari D, Thorel D, Dodu C, Gouget B, Nalbandian E, Broyer M: Protein diet and uremic toxicity: Myth or reality? S-62
Klok M *See* Daugirdas JT..... 39
Ko YH *See* Scharschmidt LA..... 700
Koegel R (abst) 438
Koehl C *See* Jahn HA S-197
Koene RAP (abst) 772, 775
Köhler H: Fluid metabolism in exercise s-93
Kohse KP, Graser TA, Fürst P, Franz HE: Plasma levels of the carnitine precursor 6-N-Trimethyllysine and maintenance hemodialysis..... S-128
Kokko JP *See* Voelker JR..... 572
Kokuba Y *See* Fujii M..... S-153
Komoda K (abst)..... 603
Koomans HA (abst)..... 773, 774, 776
Koomans HA *See* Boer WH..... 376
Koomen GCM (abst)..... 775
Koopman MG (abst) 775
Kopito RR *See* Alper SL..... S-117
Kopple JD, Winchester J, Massry SG, Heidland A: Introduction..... S-1
Kopple JD *See* Hirschberg R 382
Kopple JD *See* Cianciaruso B S-109
Kopple JD *See* Wolfson M..... S-162
Kopple JD *See* Laidlaw SA S-191
Kopple JD *See* Hirschberg R..... S-21
Korhout Mees EJ (abst)..... 776
Korninger C *See* Speiser W..... 280
Kovarik J *See* Luger A 84
Krediet RT (abst)..... 775
Kreisberg JI *See* Pugliese F 57
Kristensen C, Parks JH, Lindheimer M, Coe FL: Reduced glomerular filtration rate and hypercalciuria in primary struvite nephrolithiasis 749
Kriz W *See* Bouby N..... S-57
Krouri A (abst)..... 604, 605
Kuchmy BL *See* Kamm DE..... 47
Kuipers FC (abst) 777
Kurokawa K *See* Jamison RL..... S-208
Kurokawa K: Calcium-regulating hormones and the kidney (Nephrology Forum)..... 760
Kuwahara T (abst)..... 434
L'Allemain G *See* Pouysségur J..... S-144
Labastie J *See* Cano N..... S-178
Labonia WD, Morelli OH Jr, Gimenez MI, Freuler PV, Morelli OH: Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients 754
Lacombe P *See* Cano N..... S-178
Lacoste M *See* Mounier F..... 684
LaFrance ND *See* Walser M..... 123
Laidlaw SA, Smolin LA, Davidson WD, Kopple JD: Sulfur amino acids in maintenance hemodialysis patients S-191
Lamas J (abst) 629
Lamas S (abst) 612, 615, 616
Lameire N (abst) 778
Lamont HH *See* Vanholder RC 117
Lampreabe I (abst)..... 615, 626
Landmann J (abst) 431
Langer R *See* Bernstein H..... 452
Lankester M *See* Cano N..... S-178
Laouari D *See* Kleinknecht C S-62
Laouari D, Rocchiccioli F, Dodu C, Kleinknecht C, Broyer M: Conversion efficiency of two branched-chain α ketoanalogs in normal and uremic rats..... S-186
Laradi A (abst)..... 605
Lardi A (abst)..... 604
Largiadèr F GK (abst)..... 432
Lauzurica R (abst)..... 613
Laveri LA *See* Wolfert AI..... 246
Lazdunski M *See* Frelin C..... 785
Le Hir M (abst) 435
Le Petit JC (abst)..... 606
Lebkiri B *See* Jungers P..... S-67
Ledingham JGG, Crowe MJ, Forsling ML, Phillips PA, Rolls BJ: Effects of aging on vasopressin secretion, water excretion, and thirst in man S-90
Lee DBN *See* Corry DB 256
Lee DM *See* McCarron DA..... S-249
Lefevre A (abst)..... 774
Lefkowitz RJ *See* Dohlman HG S-2
Lefkowitz RJ *See* Schrier RW..... S-38
Lefkowitz RJ *See* Giebisch GH..... S-51
Leinfelder J *See* Voelker JR 572
Lele PS, Dunn SR, Simenhoff ML: Nutritional and metabolic modulation of the carcinogen nitrosodimethylamine in chronic renal failure..... S-159
Lelongt B, Makino H, Kanwar YS: Maturation of the developing renal glomerulus with respect to basement membrane proteoglycans 498
Lens XM (abst) 623, 624
Leon AA *See* Gardner KD 329
Leski M (abst) 435
Lesniak M *See* Roth J S-56
Leumann EP (abst) 438
Levinsky NG *See* Beasley D..... 26
Lévy M (abst) 435
Lewis EJ *See* Schwartz MM..... 274
Lewis EJ *See* Pugliese F..... 57
Liaño F (abst) 616
Lindheimer M *See* Kristensen C..... 749
Llach F (abst)..... 622
Llach F *See* London GM..... 900
Llach F *See* Metcoff J S-136
Llopart E (abst)..... 624
Llopis L A (abst)..... 617
Llorach I (abst)..... 611, 612, 613
Lloveras J (abst)..... 610, 611, 612, 613, 617, 618
Lobatto S (abst)..... 777
Lodish HF *See* Alper SL..... S-117
LoGreco P *See* Guarnieri G S-116
London AM *See* London GM..... 900
London GM, De Vernejoul M-C, Fabiani F, Marchais SJ, Guerin AP, Metivier F, London AM, Llach F: Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients..... 900
Lopez de Novales E (abst) 625
López J (abst)..... 623, 624
Lopez Larrea C (abst) 616
López Novoa JM (abst)..... 628
Lopez-Pedret J (abst)..... 624

Lopez-Rivas A (abst) . . . 618
Lorenzo V (abst) . . . 623
Loschiavo C *See* Maschio G . . . S-49
Lott RL *See* Sanders PW . . . 851
Lozano F (abst) . . . 617
Lozano L (abst) . . . 627, 628
Lucas PA *See* Merke J . . . 204
Luft FC, Weinberger MH: Sodium sensitivity and resistance of blood pressure: The role of the kidney and the renin-aldosterone axis . . . S-234
Luger A, Kovarik J, Stummvoll H-K, Urbanska A, Luger TA: Blood-membrane interaction in hemodialysis leads to increased cytokine production . 84
Luger TA *See* Luger A . . . 84
Lumbreras C (abst) . . . 614
Lund D *See* Bernstein H . . . 452
Luño J (abst) . . . 621, 627
Lupo A *See* Maschio G . . . S-49
Ma L-Y *See* Zimmerman EA . . . S-14
Macías JF (abst) . . . 618, 627
MacKay K, Striker LJ, Pinkert CA, Brinster RL, Striker GE: Glomerulosclerosis and renal cysts in mice transgenic for the early region of SV40 . . . 827
Mactier RA, Khanna R, Twardowski ZJ, Nolph KD: Role of peritoneal cavity lymphatic absorption in peritoneal dialysis (Editorial Review) . . . 165
Mactier R *See* Nolph KD . . . 219
Madero R (abst) . . . 619
Madrenas J (abst) . . . 612, 614, 619
Maduell F (abst) . . . 626
Maehara K *See* Yoshikawa N . . . 585
Maggiore Q, Enia G, Catalano C, Misefari V, Mundo A: Effect of blood cooling on Cuprophan-induced anaphylatoxin generation . . . 908
Magnaldo I *See* Pouysségur J . . . S-144
Mah SC *See* Hofbauer KG . . . S-76
Mak RHK, Turner C, Thompson T, Haycock G, Chantler C: Glucose metabolism in children with uremia: Effect of dietary phosphate and protein . . . S-206
Maki S *See* Takemura T . . . 102
Maki S *See* Yoshioka K . . . 284
Makino H *See* Lelongt B . . . 498
Mall G *See* Merke J . . . 350
Mallfré JM (abst) . . . 610
Mallick NP *See* Mistry CD . . . S-210
Mallol J (abst) . . . 620
Malnic G: H^{pr}+ secretion in renal cortical tubules: Kinetic aspects (Robert F. Pitts Memorial Lectu) . . . 136
Mampaso F (abst) . . . 610, 627
Man NK *See* Jungers P . . . S-67
Mann JFE, Johnson AK, Ganten D, Ritz E: Thirst and the renin-angiotensin system . . . S-27
Mannik M *See* Agodoa LYC . . . 13
Mañoso LL (abst) . . . 611
Maoui R (abst) . . . 605
Marcén R (abst) . . . 615, 616
Marchais SJ *See* London GM . . . 900
Marcuccio F *See* Cianciaruso B . . . S-109
Marin R (abst) . . . 616
Markert M (abst) . . . 434
Maroni BJ *See* Mitch WE . . . S-104
Marsh FP *See* Altmann P . . . 710
Martin KJ *See* Galceran T . . . 801
Martín Malo A (abst) . . . 620
Martin TJ *See* Sexton PM . . . 862
Martinez A (abst) . . . 616
Martinez Ara J (abst) . . . 626
Martinez F (abst) . . . 435
Martinez J (abst) . . . 626
Martinez ME (abst) . . . 611, 615, 617
Martinez Vea A (abst) . . . 620
Martinez-Amenós A (abst) . . . 614
Martin-Luengo C (abst) . . . 618
Martin-Malo A (abst) . . . 620
Martorell J (abst) . . . 611, 617
Masaramon J (abst) . . . 613
Maschio G *See* Rugiu C . . . S-29
Maschio G, Oldrizzi L, Rugiu C, Valvo E, Lupo A, Loschiavo C, Tessitore N, Fabris A, Gammaro L, Panzetta G: Factors affecting progression of renal failure in patients on long-term dietary protein restriction . . . S-49
Masramon J (abst) . . . 610, 611, 612, 617, 618
Massry SG *See* Kopple JD . . . S-1
Masur SK *See* Alawqati Q . . . S-162
Masur SK *See* Fanestil DD . . . S-196
Masur SK *See* Jamison RL . . . S-208
Masur SK *See* Giebisch GH . . . S-51
Masur SK *See* Handler JS . . . S-94
Mateo S (abst) . . . 614
Matesanz R (abst) . . . 611, 616
Matinez ME (abst) . . . 622
Matsumoto K *See* Takemura T . . . 102
Matsuo T *See* Yoshikawa N . . . 585
Matter DR (abst) . . . 435
Matter EE (abst) . . . 435
Mattera R *See* Birnbaumer L . . . S-14
Matthys E (abst) . . . 778
Mauer SM (abst) . . . 619
Mauer SM *See* Ellis EN . . . 736
Mauer SM *See* Bilous RW . . . 930
Maxwell MH *See* Dornfeld LP . . . S-254
May RC *See* Hara Y . . . 808
May RC *See* Mitch WE . . . S-104
McCann RL *See* Schwab SJ . . . 395
McCarron DA, Shneidman RJ, Lee DM: $Ca^{pr}2+$ Defects in experimental hypertension: SHR's renal response to chronic infusion of human PTH (1-34) . . . S-249
McDonough A *See* Burg MB . . . S-113
McDonough A *See* Fanestil DD . . . S-196
McGarry L *See* Scharschmidt LA . . . 700
McGary T *See* Nolph KD . . . 219
McLean A *See* Smith GD . . . 96
Mcligeyo SO (abst) . . . 606
Mees EJD *See* Boer WH . . . 376
Mehta A *See* Copeland KR . . . 664
Meijer S (abst) . . . 778
Meisinger E, Strauch M: Controled Trial of two keto acid supplements on renal function, nutritional status, and bone metabolism in uremic patients . . . S-170
Mellman I: Molecular sorting during endocytosis . . . S-184
Meema HE, Oreopoulos DG, Rapoport A: Serum magnesium level and arterial calcification in end-stage renal disease . . . 388
Mendelsohn FAO *See* Sexton PM . . . 862
Merad R (abst) . . . 605
Mercén R (abst) . . . 612
Merke J, Lucas PA, Szabó A, Helbing F, Hügel U, Drüeke T, Ritz E: 1, 25$(OH)_{fr}$2 D_{fr}3 Receptors and endorgan response in experimental aluminum

intoxication 204
Merke J, Hügel U, Zlotkowski A, Szabó A, Bommer J, Mall G, Ritz E: Diminished parathyroid 1, 25(OH)$_{fr}$2 D$_{fr}$3 receptors in experimental uremia 350
Merola E (abst) 621
Merottani A (abst) 604
Metcoff J, Pederson J, Gable J III, Llach F: Protein synthesis, cellular amino acids, and energy levels in CAPD patients S-136
Metivier F *See* London GM 900
Metry J (abst) 607
Michel MC *See* Daul AE 728
Michielsen P (abst) 774
Miguel JL (abst) 612, 618, 619, 622
Mihatsch MJ (abst) 431, 437
Mikani H *See* Fujii M S-153
Mikhailidis DP *See* Grace AA 889
Milad M (abst) 608
Millas I (abst) 628
Miller NL *See* Ittel TH 821
Mion C *See* Argiles A 714
Mioni G *See* Guarnieri G S-116
Mir M (abst) 610, 611, 612, 617, 618
Miranda B (abst) 614
Mirapeix E (abst) 622
Miro JM (abst) 623
Misefari V *See* Maggiore Q 908
Mistry CD, Fox JE, Mallick NP, Gokal R: Circulating maltose and isomaltose in chronic renal failure . . . S-210
Mitch WE, May RC, Clark AS, Maroni BJ, Kelly RA: Influence of insulin resistance and amino acide supply on muscle protein turnover in uremia S-104
Mitch WE *See* Hara Y 808
Miyamoto H *See* Takemura T 102
Miyamoto H *See* Yoshioka K 284
Moll R (abst) 622
Monnens L (abst) 776
Montenegro J (abst) 615
Montoliu J (abst) 623, 624
Moore H *See* Nolph KD 219
Moorhead JF *See* Grace AA 889
Morales JM (abst) 614
Morales P (abst) 621
Morelli OH *See* Labonia WD 754
Morelli OH Jr *See* Labonia WD 754
Moreno R (abst) 610, 617
Morino Y *See* Inoue M 198
Morrison AR *See* Heifets M 335
Morrissey JJ *See* Heifets M 335
Morrissey JJ *See* Galceran T 801
Morsing P, Stenberg A, Müller-Suur C, Persson AEG: Tubuloglomerular feedback in animals with unilateral, partial ureteral occlusion 212
Mosaad A (abst) 608
Moseley JM *See* Sexton PM 862
Mounier F, Hinglais N, Sich M, Gros F, Lacoste M, Deris Y, Alhene-Gelas F, Gubler M-C: Ontogenesis of angiotensin-I converting enzyme in human kidney 684
Mourad G *See* Argiles A 714
Moustafa F (abst) 603, 605
Müller-Suur C *See* Morsing P 212
Mundo A *See* Maggiore Q 908
Munné A (abst) 611
Muñoz Gomez J (abst) 624
Muñoz J (abst) 617, 618, 619
Murer H *See* Andreoli TE S-141
Musa AM (abst) 605
Naga S (abst) 604
Nagase S *See* Inoue M 198
Nagase S *See* Aoyagi K S-229
Najarian JS (abst) 619
Nalbandian E *See* Kleinknecht C S-62
Naranjo J (abst) 615
Naranjo P (abst) 613, 615
Narita M *See* Aoyagi K S-229
Navar LG *See* Klahr S S-77
Naves M (abst) 622
Nawab ZM *See* Daugirdas JT 39
Nemmar M (abst) 608
Nenniger M (abst) 432, 434
Niembro E (abst) 627
Nieto J (abst) 614
Nigrelli S (abst) 613
Nilaver G *See* Zimmerman EA S-14
Nolph KD *See* Mactier RA 165
Nolph KD, Mactier R, Khanna R, Twardowski ZJ, Moore H, McGary T: The kinetics of ultrafiltration during peritoneal dialysis: The role of lymphatics . . . 219
Northrup TE *See* Borkan S 322
Nushior N *See* Itoh S 493
Nussberger J *See* Biollaz J 537
Nyakundi PM (abst) 604
O Khashab O (abst) 608
Ochi RF *See* Johnson RJ 342
Oetliker O (abst) 438
Okada A *See* Fujii M S-153
Okada S *See* Yoshikawa N 585
Okajima K *See* Inoue M 198
Oken DE *See* Wolfert AI 246
Oken KR *See* Wolfert AI 246
Olbricht CJ, Cannon JK, Tisher CC: Cathepsin B and L in nephron segments of rats with puromycin aminonucleoside nephrosis 354
Oldrizzi L *See* Rugiu C S-29
Oldrizzi L *See* Maschio G S-49
Oleggini R *See* Ghiggeri GM 547
Oliet A (abst) 614
Oliver A (abst) 619
Oliver JA (abst) 620
Olivera A (abst) 628
Olmos A (abst) 614
Omata K *See* Itoh S 493
Ongeri SK (abst) 606
Oppenheimer F (abst) 611
Ordinas A (abst) 623, 624
Oreopoulos DG *See* Memma HE 388
Orfila A (abst) 610, 611, 612, 617
Orfila O (abst) 618
Orita Y *See* Fujii M S-153
Orofino G *See* Cianciaruso B S-109
Orofino L (abst) 612, 615, 616
Orte L (abst) 611, 616
Ortega Marcos O (abst) 626
Ortíz A (abst) 627
Ortuño J (abst) 610, 611, 612, 615, 616
Osman EM (abst) 608
Otieno LS (abst) 606
Oudinet J-P *See* Sraer, J 62
Oza NB *See* Beasley D 26

Pabst W *See* Rawer P. . . . S-149
Pace E *See* Wesson DE. . . . 238
Palade G *See* Warnock DG S-129
Palade G *See* Alawqati Q. . . . S-162
Palazon X (abst). . . . 611
Pallardo J (abst) 617
Pallardo L (abst). . . . 610, 617
Pannain M *See* Conte G 721
Panzetta G *See* Maschio G S-49
Paoletti E *See* Tizianello A S-181
Pardo A (abst) 615
Paris S *See* Pouysségur J S-144
Parks JH *See* Kristensen C 749
Pascal S *See* Cano N S-178
Pasquier R *See* Pelletier L. . . . 227
Pastor MC (abst) 613
Patrono C, Dunn MJ: The clinical significance of inhibition of renal prostaglandin synthesis (Editorial Review). . . . 1
Paunier L (abst). . . . 438
Paunier L *See* Salusky IB 89
Pauwels EKJ (abst) 777
Pauwels R (abst) 777
Pauwels RA *See* Vanholder RC 117
Paviotti G *See* Guarnieri G S-116
Pearson PL (abst). . . . 772
Pederson J *See* Metcoff J S-136
Pedro C (abst) 622
Pelletier L, Galceran M, Pasquier R, Ronco P, Verroust P, Bariety J, Druet P: Down modulation of Heymann's nephritis by mercuric chloride 227
Penner B *See* Copeland KR 664
Perez A (abst) 622
Perez-Garcia R (abst). . . . 621
Perfumo F *See* Ghiggeri GM 69, 547
Perrez Fontan M (abst) 612
Persson AEG *See* Morsing P. . . . 212
Pestano M (abst) 623
Peter G *See* Heidland A. . . . S-94
Petrone A *See* Cianciaruso B. . . . S-109
Philippart Y *See* Dhaene M S-25
Phillips PA *See* Ledingham JGG S-90
Picazo ML (abst) 612
Piera C (abst) 621
Piera L (abst) 612, 614, 619
Pinkert CA *See* MacKay K. . . . 827
Pintó X (abst). . . . 614
Pintos Morell G (abst) 614
Pintos-Morell G *See* Pirotzky E 233
Pirotzky E (abst) 614
Pirotzky E, Pintos-Morell G, Burtin C, Boudet J, Bidault J, Benveniste J: Renal anaphylaxis. I. Antigen-initiated responses from isolated perfused rat kidney 233
Pizurki L (abst) 435
PJJ (abst) 772
Plana J (abst) 614
Plana M (abst) 617
Plass R, Schaefer RM, Heidland A, Hörl WH: Glycerol-induced acute renal failure in the rat: Protection by exercise. . . . S-113
Plaza JJ (abst) 627
Plowman D *See* Altmann P 710
Ployard F *See* Jungers P S-67
Pocino M (abst) 621
Pollack AS *See* Handler JS S-94
Pons J (abst). . . . 621
Pons JM (abst) 621
Porush JG *See* Faubert PF 472
Pouysségur J, Franchi A, L'Allemain G, Magnaldo I, Paris S, Sardet C: Genetic approach to structure, function, and regulation of the $Na^{pr}+$ $H^{pr}+$ antiporter S-144
Poveda R (abst) 612
Praga M (abst) 614
Preisig R (abst). . . . 433
Prieto J (abst). . . . 626
Probst PJ (abst) 438
Provoost AP (abst). . . . 772, 775
Pugliese F, Singh AK, Kasinath BS, Kreisberg JI, Lewis EJ: Glomerular epithelial cell, plyanion neutralization is associated with enhanced prostanoid production. . . . 57
Puig JM (abst) 610, 613
Pujol JL (abst) 620
Purkerson ML *See* Heifets M 335
Purkerson ML *See* Klahr S S-35
Purroy A (abst). . . . 625, 626
Pusterla C (abst). . . . 432
Queirolo C *See* Ghiggeri GM. . . . 69, 547
Quereda C (abst) 612, 615, 616
Quintela J (abst) 611
Quinton PM: Physiology of sweat secretion S-102
Rabkin R *See* Fanestil DD. . . . S-196
Rabkin R *See* Brenner BM S-61
Radl J (abst). . . . 774
Radwan M (abst) 607, 609
Rafizadeh C (abst) 435
Rahman MA, Stork JE, Dunn MJ: The roles of eicosanoids in experimental glomerulonephritis S-40
Ramos B (abst). . . . 625
Ramos I (abst) 627
Ramos OL *See* Barros EJG. . . . 19
Ramzy M (abst) 603
Randhawa M *See* Bernstein H 452
Rapado A (abst). . . . 629
Rapoport A *See* Memma HE. . . . 388
Rascher W (abst) 776
Rascher W, Tulassay T: Hormonal regulation of water metabolism in children with nephrotic syndrome. . . S-83
Rashad AL *See* Elzinga LW 884
Rastorfer M (abst) 438
Rawer P, Willems WR, Breidenbach Th, Guttmann W, Pabst W, Schütterle G: Seroconversin rate, hepatitis B vaccination, hemodialysis, and zinc supplementation. . . . S-149
Razzak M (abst). . . . 606
Rebstöck W III (abst) 433
Rector FC, Bacallao R, Ives HE, Alper SL, Daniel TO, Jamison RL, Schreiner GF Jr, Dousa TP, Roth J: Discussion: Drickamer, Membrane receptors for endocytosis of glycoproteins. . . . S-181
Rector FC Jr *See* Fanestil DD. . . . S-196
Redman CWG: Hypertension in pregnancy: A case discussion (Nephrology Forum). . . . 151
Reed WP *See* Gardner KD 329
Reeders ST (abst). . . . 772
Rees AJ *See* El Nahas AM 173
Reeves WB *See* Andreoli TE. . . . S-141
Refoyo A (abst) 627

Rehim FA (abst) 606
Reilly KM *See* Wolfert AI 246
Reitsma WD (abst) 778
Remuzzi G: HUS and TTP: Variable expression of a single entity (Nephrology Forum) 292
Renner E (abst) 433
Rennke HG *See* Andreoli TE S-141
Rennke HG *See* Alawqati Q S-162
Reutter FW (abst) 438
Revert L (abst) 621, 622, 623, 624
Rey J (abst) 614
Riambau E (abst) 610
Riancho J (abst) 619
Ricanati ES, Tserng K-Y, Hoppel CL: Abnormal fatty acid utilization during prolonged fasting in chronic uremia S-145
Ricart MJ (abst) 611
Richards GK *See* Gallimore B 678
Richart C (abst) 620
Richelsen B *See* Eriksen EF 181
Richter D *See* Schmale H S-8
Riesen W (abst) 433
Rifai A, Chen A, Imai H: Complement activation in experimental IgA nephropathy: An antigen-mediated process 838
Rihan ZE (abst) 604
Ringoir S (abst) 613, 777
Ringoir SM *See* Vanholder RC 117
Riñon C (abst) 618
Ritz E (abst) 431
Ritz E *See* Merke J 204
Ritz E *See* Merke J 350
Ritz E *See* Gross P S-1
Ritz E *See* Mann JFE S-27
Ritz E *See* Hasslacher C S-53
Ritz E *See* Gross PA S-67
Rius E (abst) 610
Rivas C (abst) 627
Rivera F (abst) 620
Rizzoli R (abst) 435
Robaudo C *See* Tizianello A S-181
Robelink AJ (abst) 774
Robert D (abst) 433
Robertson GL: Physiology of ADH secretion S-20
Robertson JIS: Salt, volume, and hypertension: Causation or correlation? (Nephrology Forum) 590
Robinson RR *See* Jacobson HR S-1
Robles A (abst) 627
Robles JE (abst) 625
Robotii G (abst) 434
Robson JS *See* Smith GD 96
Rocchiccioli F *See* Laouari D S-186
Rodamilans M (abst) 619
Rodicio JL (abst) 614
Rodriguez A (abst) 623
Rodriguez JA (abst) 614
Rodriguez JC (abst) 623
Rodríguez Puyol D (abst) 628
Rodriguez-Carmona A (abst) 626
Rolls BJ *See* Ledingham JGG S-90
Roma J (abst) 610
Romero M (abst) 614
Romero R (abst) 611, 613
Ronco P *See* Pelletier L 227
Roos JC (abst) 775
Rossier B *See* Burg MB S-113
Rössle C *See* Wanner C S-132
Roth J *See* Warnock DG S-129
Roth J *See* Rector FC S-181
Roth J *See* Schrier RW S-38
Roth J *See* Giebisch GH S-51
Roth J *See* Klahr S S-77
Roth J *See* Stein JH S-8
Roth J, Lesniak M, Hill JM: Hormone receptor interactions: An overview S-56
Rouse D, Dalmeida W, Williamson FC, Suki WN: Captopril inhibits the dydroosmotic effect of ADH in the cortical collecting tubule 845
Rugiu C *See* Maschio G S-49
Rugiu C, Oldrizzi L, Maschio G: Effects of an oral protein load on glomerular filtration rate in patients with solitary kidneys S-29
Ruilope LM (abst) 614
Ruiz L (abst) 621
Rumpelt H-J *See* Fries JWU 742
Russel M (abst) 775
Russell DW: The study of natural and synthetic mutations in the LDL receptor S-156
Russo D *See* Conte G 721
Sabate F (abst) 624
Sabater J (abst) 616
Sabot J-P *See* Dhaene M S-25
Saccà L *See* Cianciaruso B S-109
Sacktor B *See* Schrier RW S-38
Saeed M *See* Schwab SJ 395
Saffioti S *See* Tizianello A S-181
Saingra S *See* Cano N S-178
Saito T, Sumithran E, Glasgow EF, Atkins RC: The enhancement of aminonucleoside nephrosis by the co-administration of protamine 691
Salah H (abst) 608
Salant DJ: Immunopathogenesis of crescentic glomerulonephritis and lung purpura (Nephrology Forum) 408
Salem M (abst) 603
Salusky IB, Fine RN, Kangarloo H, Gold R, Paunier L, Goodman WG, Brill JE, Gilli G, Slatopolsky E, Coburn JW: "High-dose" calcitriol for control of renal osteodystrophy in children on CAPD 89
Saluzzo JP (abst) 603
Salvatierra A (abst) 620
Salvidio G *See* Tizianello A S-181
Sánchez Bayle M (abst) 611
Sanchez J (abst) 610, 617
Sanchez M (abst) 621
Sanchez Sicilia L (abst) 619, 626
Sanchez-Sicilia L (abst) 617, 618
Sanchis J (abst) 622
Sancho J (abst) 614, 627
Sanders PW, Herrera GA, Galla JH, Hancock JR, Lott RL: Human Bence Jones protein toxicity in rat proximal tubule epithelium in vivo 851
Sans M (abst) 619
Santaló M (abst) 614
Santoro A (abst) 613
Sanz A (abst) 612, 617, 618, 626
Sanz de Castro S (abst) 621
Sanz-Moreno C (abst) 613
Saracho R (abst) 626
Sardet C *See* Pouysségur J S-144

Saurer F (abst) 437
Saxenhofer H (abst) 434
Saxenhofer H, Gnädinger MP, Wiedmann P, Shaw S, Schohn D, Hess C, Uehlinger DE, Jahn H: Plasma levels and dialysance of atrial peptide in terminal renal failure 554
Sayed AB (abst) 608
Schaad HJ (abst) 433
Schaap GH (abst) 775
Schaefer RM *See* Plass R S-113
Schaefer RM *See* Heidland A S-94
Schaefer RM, Heidland A, Hörl WH: Leukocyte proteinases and proteinase inhibitors in the catabolism of acute renal failure S-100
Schafferhans K *See* Heidbreder E S-221
Schalekamp MADH (abst) 777
Schäli C (abst) 435
Schardijn GHC, van Eps LWS: β_2-microglobulin: Its significance in the evaluation of renal function (Editorial Review) 635
Scharschmidt LA, Gibbons NB, McGarry L, Berger P, Axelrod M, Janis R, Ko YH: Effects of dietary fish oil on renal insufficiency in rats with subtotal nephrectomy 700
Scheidegger JR (abst) 434
Scherer N *See* Birnbaumer L S-14
Schlondorff DO *See* Schrier RW S-38
Schmale H, Fehr S, Richter D: Vasopressin biosynthesis—from gene to peptide hormone S-8
Schmitt RL *See* Jahn HA S-197
Schohn D *See* Saxenhofer H 554
Schohn DC *See* Jahn HA S-197
Schöllhammer Th (abst) 436
Schollmeyer P *See* Wanner C S-132
Scholz R *See* Seyffart G S-174
Schor N *See* Barros EJG 19
Schreiner GE Jr *See* Schrier RW S-38
Schreiner GF Jr *See* Rector FC S-181
Schrier RW *See* Jamison RL S-208
Schrier RW *See* Klahr S S-77
Schrier RW *See* Brenner BM S-61
Schrier RW *See* Stein JH S-8
Schrier RW, Arnold PE, Van Putten VJ, Burke TJ: Cellular calcium in ischemic acute renal failure: Role of calcium entry blockers (Editorial Review) 313
Schrier RW, Kim JK: Water metabolism in historical perspectives: Its research in the past and present . S-113
Schrier RW, Berl T, Sacktor B, Lefkowitz RJ, Skorecki CL, Schlondorff DO, Schreiner GE Jr, Roth J: Discussion: Birnbaumer et al, Signal transduction .. S-38
Schultz SG *See* Burg MB S-113
Schulz W (abst) 433, 436
Schulz W III (abst) 433
Schuster VL *See* Warnock DG S-129
Schütterle G *See* Rawer P S-149
Schwab SJ, Saeed M, Sussman SK, McCann RL, Stickel DL: Transluminal angioplasty of venous stenoses in polytetrafluoroethylene vascular access grafts. 395
Schwartz GJ *See* Warnock DG S-129
Schwartz GJ *See* Alawqati Q S-162
Schwartz MM, Kawala KS, Corwin HL, Lewis EJ: The prognosis of segmental glomerulonephritis in systemic lupus erythematosus 274
Sege D (abst) 438
Seifter JL *See* Brenner BM S-61
Selgas R (abst) 612, 617, 618, 619, 622
Semmekrot B (abst) 776
Serra A (abst) 613
Serrano S (abst) 611
Sert S (abst) 604
Sexton PM, Ada WR, Moseley JM, Martin TJ, Mendelsohn FAO: Localization and characterization of renal calcitonin receptors by in vitro autoradiography 862
Seyffart G, Ensminger A, Scholz R: Increase of body mass during long-term bicarbonate hemodialysis .. S-174
Sharoubim R (abst) 608
Shaw S (abst) 432, 434, 435, 436
Shaw SG (abst) 436
Shaw S *See* Saxenhofer H 554
Shneidman RJ *See* McCarron DA S-249
Sica DA *See* Voelker JR 572
Sich M *See* Mounier F 684
Sicilia AT (abst) 612
Sicilia LS (abst) 612, 622
Sigler MH, Teehan BP, Van Valkenburgh D: Solute transport in continuous hemodialysis: A new treatment for acute renal failure 562
Silva P: Renal fuel utilization, energy requirements, and function S-9
Simenhoff ML *See* Lele PS S-159
Simons K: Membrane traffic in an epithelial cell line derived from the dog kidney S-201
Singh AK *See* Pugliese F 57
Singoir S (abst) 607
Situlin R *See* Guarnieri G S-116
Skorecki CL *See* Aronson PS S-150
Skorecki CL *See* Schrier RW S-38
Skorecki CL *See* Giebisch GH S-51
Skorecki CL *See* Brenner BM S-61
Skorecki CL *See* Klahr S S-77
Skorecki CL *See* Stein JH S-8
Skorecki KL *See* Ausiello DA S-43
Slatopolsky E *See* Galceran T 801
Slatopolsky E *See* Salusky IB 89
Sluiter HE (abst) 772
Smit AJ (abst) 778
Smith GD, Winney RJ, McLean A, Robson JS: Aluminum-related osteomalacia: Response to reverse osmosis water treatment 96
Smolin LA *See* Laidlaw SA S-191
Sobh M (abst) 603, 605
Sobh MA (abst) 603
Sola R (abst) 611, 617
Soliman M (abst) 604, 605, 606, 607, 608, 609
Sonseca A (abst) 611
Sothi TD *See* Ellis D 464
Sparks L *See* Johnson RJ 342
Speiser W, Wojta J, Korninger C, Kirchheimer JC, Zazgornik J, Binder BR: Enhanced fibrinolysis caused by tissue plasminogen activator release in hemodialysis 280
Spiliopoulos A (abst) 435
Sraer J-D *See* Sraer, J 62
Sraer, J, Wolf C, Oudinet J-P, Bens M, Ardaillou R, Sraer J-D: Human glomeruli release fatty acids which stimulate thromboxane synthesis in platelets .. 62
Städler P (abst) 432
Steffes MW *See* Ellis EN 736
Steffes MW *See* Bilous RW 930

Stein JH, Dousa TP, Ballerman BJ, Ausiello DA, Birnbaumer L, Bernstein KE, Roth J, Skorecki CL, Schrier RW: Discussion: Dohlman et al, β_{fr}2-adrenergic receptor structure and function S-8
Stenberg A *See* Morsing P 212
Stengaard-Pedersen K *See* Eriksen EF 181
Stenzel KH *See* Suthanthiran M 362
Stickel DL *See* Schwab SJ 395
Stokes JB *See* Jamison RL S-208
Stokes JB *See* Klahr S S-77
Stone DK *See* Fanestil DD S-196
Stork JE *See* Rahman MA S-40
Strauch M *See* Meisinger E S-170
Striker GE *See* MacKay K 827
Striker GE *See* Brenner BM S-61
Striker LJ *See* MacKay K 827
Stummvoll H-K *See* Luger A 84
Sturgill BC *See* Bolton WK 869
Suki WN *See* Rouse D 845
Sulieman SM (abst) 605
Sumithran E *See* Saito T 691
Sussman SK *See* Schwab SJ 395
Suthanthiran M, Wiebe ME, Stenzel KH: Effect of immunosuppressants on OKT3 associated T cell activation: Clinical implications 362
Sutherland DER (abst) 619
Sweny P *See* Grace AA 889
Szabó A *See* Merke J 204
Szabó A *See* Merke J 350
Tabernero JM (abst) 618
Takemura T, Yoshioka K, Akano N, Miyamoto H, Matsumoto K, Maki S: Glomerular deposition of cross-linked fibrin in human kidney diseases 102
Takemura T *See* Yoshioka K 284
Takeyasu K *See* Fambrough DM S-97
Tamkun MM *See* Fambrough DM S-97
Tannen RL: The influence of potassium on blood presure S-242
Teehan BP *See* Sigler MH 562
Tegtmeyer E *See* Heifets M 815
Teixido J (abst) 611, 613
ten Kate FJW (abst) 777
Teo KK, Basile C, Ulan RA, Hetherington MD, Kappagoda T: Effects of hemodialysis and hypertonic hemodiafiltration on cardiac function compared 399
Tepper T (abst) 773
Terracciano V *See* Cianciaruso B S-109
Terribile M *See* Conte G 721
Teruel JL (abst) 610, 615, 616
Tessitore N *See* Maschio G S-49
Tetteroo PAT (abst) 779
The TH (abst) 779
Theelen B (abst) 776
Thiel G (abst) 431, 437
Thliveris JA *See* Copeland KR 664
Thoenes W *See* Fries JWU 742
Thomas M (abst) 603
Thompson T *See* Mak RHK S-206
Thorel D *See* Kleinknecht C S-62
Tiebosch ATMG, Wolters J, Frederik PFM, van der Wiel TWM, Zeppenfeldt E, van Breda Vriesman PJC, van Rie H: Epidemiology of idiopathic glomerular disease: A prospective study 112
Tielemans C *See* Dratwa M S-32
Tisher CC *See* Olbricht CJ 354
Tizianello A, Deferrari G, Garibotto G, Robaudo C, Saffioti S, Salvidio G, Paoletti E: Abnormal amino acid metabolism after amino acid ingestion in chronic renal failure S-181
Toigo G *See* Guarnieri G S-116
Tojo S *See* Aoyagi K S-229
Toro M-J *See* Birnbaumer L S-14
Torras A (abst) 623, 624
Torrente J (abst) 613
Torrents J (abst) 610
Torres A (abst) 623
Trinh-Trang-Tan M-M *See* Bouby N S-57
Tschudi M (abst) 431
Tserng K-Y *See* Ricanati ES S-145
Tuck M *See* Dornfeld LP S-254
Tuck ML *See* Corry DB 256
Tulassay T *See* Rascher W S-83
Turá J (abst) 611
Turner C *See* Greene SA 896
Turner C *See* Mak RHK S-206
Twardowski ZJ *See* Mactier RA 165
Twardowski ZJ *See* Nolph KD 219
Tzogalis D (abst) 437
Ubeda I (abst) 615
Uehlinger DE (abst) 434, 435, 436
Uehlinger DE *See* Saxenhofer H 554
Ulan RA *See* Teo KK 399
Ulich TR *See* Bannister KM 642
Ullrich KJ *See* Klahr S S-77
Ura N, Carretero OA, Erdös EG: Role of renal endopeptidase 24.11 in kinin metabloism in vitro and in vivo 507
Urbanska A *See* Luger A 84
Urra M (abst) 626
Urrutia M (abst) 618
v Munster (abst) 772
Valderrabano F (abst) 621, 627
Vallés M (abst) 612
Valverde C VM (abst) 617
Valvo E *See* Maschio G S-49
van Aken M (abst) 775
van Breda Vriesman PJC *See* Tiebosch ATMG 112
Van Den Bogaerde J (abst) 777
van den Wall Bake AWL (abst) 774
van der Ark A (abst) 774
van der Giessen M (abst) 778
van der Groen G (abst) 774
Van Der Groens G (abst) 603
van der Hem GK (abst) 773, 778
van der Hem GK *See* Heeg JE 78
Van Der Straeten ME *See* Vanholder RC 117
van der Wal A *See* Beukers JJB 794
van der Wiel TWM *See* Tiebosch ATMG 112
van der Woude FJ (abst) 778
van Eps LSW *See* Schardijn GHC 635
van Es AL (abst) 772
van Es LA (abst) 774, 777
van Geelen JA (abst) 777
Van Gossum M *See* Dratwa M S-32
van Guldener C (abst) 772
van Heusden FHJA (abst) 775
Van Putten VJ *See* Schrier RW 313
van Rie H *See* Tiebosch ATMG 112
Van Rijssel RH (abst) 777

Van Valkenburgh D *See* Sigler MH 562
Vandenbogaerde JF *See* Vanholder RC 117
Vanderstraeten M (abst) 777
VanDuyn MA *See* Walser M 123
Vanherweghem J-L *See* Dhaene M S-25
Vanholder R (abst) 607, 613, 777
Vanholder RC, Pauwels RA, Vandenbogaerde JF, Lamont HH, Van Der Straeten ME, Ringoir SM: Cuprophan reuse and intradialytic changes of lung diffusion capacity and blood gasses 117
Varela JI (abst) 626
Vázquez-Martul M (abst) 611
vd Broek LJCM (abst) 774
Verberckmoes R (abst) 774
Verkman A *See* Giebisch GH S-51
Verkman AS *See* Ausiello DA S-43
Verroust P *See* Pelletier L 227
Versluis DJ (abst) 777
Vigne P *See* Frelin C 785
Vila A (abst) 617
Villa E (abst) 611
Viñas O (abst) 617
Vincent HH (abst) 777
Virgen de la Salud RS (abst) 622
Vives J (abst) 617
Voelker JR, Cartwright-Brown D, Anderson S, Leinfelder J, Sica DA, Kokko JP, Brater DC: Comparison of loop diuretics in patients with chronic renal insufficiency 572
Voetman AA (abst) 777
von dem Borne AEGKR (abst) 779
Waeber B *See* Biollaz J 537
Wairagu SG (abst) 606
Waks A *See* Dornfeld LP S-254
Wal AMyd (abst) 772
Walser M, LaFrance ND, Ward L, VanDuyn MA: Progression of chronic renal failure in aptients given ketoacids following amino acids 123
Walters BK *See* Wesson DE 238
WAng XL *See* Daul AE 728
Wanner C, Förstner-Wanner S, Rössle C, Fürst P, Schollmeyer P, Hörl WH: Carnitine metabolism in patients with chronic renal failure: Effect of L-carnitine supplementation S-132
Ward L *See* Walser M 123
Ward MK (abst) 620
Ward RA, Wathen RL, Williams TE, Harding GB: Hemodialysate composition and intradialytic metabolic, acid-base and potassium changes 129
Warnock DG *See* Andreoli TE S-141
Warnock DG *See* Aronson PS S-150
Warnock DG *See* Fanestil DD S-196
Warnock DG, Schwartz GJ, Schuster VL, Bacallao R, Bernstein KE, Farquhar MG, Roth J, Palade G, Brown D: Discussion: Alper et al, Molecular biology of anion transport S-129
Wassef N (abst) 605
Watanabe N *See* Inoue M 198
Waterloos M (abst) 778
Wathen RL *See* Ward RA 129
Wauters JP (abst) 434
Weening JJ (abst) 772
Weening JJ *See* Beukers JJB 794
Weidmann P (abst) 432, 434, 435, 436
Weimar W (abst) 777
Weinberger MH *See* Luft FC S-234
Weinman EJ *See* Aronson PS S-150
Weinman EJ *See* Klahr S S-77
Weipert J *See* Heidland A S-94
Wens R *See* Dratwa M S-32
Wenting GJ (abst) 777
Werner D (abst) 435
Wesseling H (abst) 778
Wesson DE, Walters BK, Dudek MA, Pace E: Glomerular filtration effects of acute volume expansion: Importance of chloride 238
West ML, Jindal KK, Bear RA, Goldstein MB: A controlled trial of cyclophosphamide in patients with membranous glomerulonephritis 579
Westerman RF (abst) 775
Wetzels JFM (abst) 772, 775, 776
Wiebe ME *See* Suthanthiran M 362
Wiedmann P *See* Saxenhofer H 554
Wiggins RC *See* Brukman J 31
Wilkinson JS *See* Fleming SJ 267
Willems J (abst) 776
Willems WR *See* Rawer P S-149
Williams DG (abst) 603
Williams TE *See* Ward RA 129
Williamson FC *See* Rouse D 845
Wilson CB *See* Yamamoto T 514
Wilson CB *See* Bannister KM 642
Wilson CB *See* Blantz RC 652
Winchester J *See* Kopple JD S-1
Winney RJ *See* Smith GD 96
Wojta J *See* Speiser W 280
Wolf C *See* Sraer, J 62
Wolfe RR *See* Jahoor F S-81
Wolfert AI, Laveri LA, Reilly KM, Oken KR, Oken DE: Glomerular hemodynamics in mercury-induced acute renal failure 246
Wolfson M, Kopple JD: The effects of vitamin B-6 deficiency in chronically azotemic and sham-operated rats S-162
Wolitzky BA *See* Fambrough DM S-97
Wolters J *See* Tiebosch ATMG 112
Wu L *See* Kamm DE 47
Yamamoto T, Wilson CB: Quantitative and qualitative studies of antibody induced mesangial cell damage in the rat 514
Yamauchi A *See* Fujii M S-153
Yang VC *See* Bernstein H 452
Yap L (abst) 626
Yasaka T *See* Inoue M 198
Yasujima M *See* Itoh S 493
Yatani A *See* Birnbaumer L S-14
Yatscoff RW *See* Copeland KR 664
Yoshiara S *See* Yoshikawa N 585
Yoshikawa N, Iijima K, Maehara K, Yoshiara S, Yoshiya K, Matsuo T, Okada S: Mesangial changes in IgA nephropathy in children 585
Yoshinaga K *See* Itoh S 493
Yoshioka K *See* Takemura T 102
Yoshioka K, Takemura T, Akano N, Miyamoto H, Iseki T, Maki S: Cellular and non-cellular compositions of crescents in human glomerulonephritis 284
Yoshiya K *See* Yoshikawa N 585
Zager RA: Amino acid hyperalimentation in acute renal failure: A potential therapeutic paradox S-72
Zahran M (abst) 604

Zaman T (abst) 436
Záruba K (abst) 438
Zawislak R *See* Jahn HA S-197
Zazgornik J *See* Speiser W 280
Zedalis J *See* Gardner KD 329
Zeppenfeldt E *See* Tiebosch ATMG 112
Zihlmann F (abst) 437
Zimmerman EA, Ma L-Y, Nilaver G: Anatomical basis of thirst and vasopressin secretion S-14
Zlotkowski A *See* Merke J 350
Zobara MA (abst) 607
Zollinger HU (abst) 437
Zoob SN *See* El Nahas AM 173
Zubimendi A (abst) 621
Zubimendi JA (abst) 619
Zucchelli P (abst) 613
Zudaire J (abst) 625

Subject Index for Volume 32

Acetate
relaxation of isolated vascular smooth muscle 39
Acid-base
balance, H+ secretion in renal cortical tubules 136
Acidification during endocytosis 23:S-184
Acidosis
azotemia, branched-chain amino acid catabolism 808
bicarbonate HD, weight gain 22:S-174
Acute cellular rejection, lymphs (abst) 615
Acute renal failure
age, GN, renal biopsy (abst) 426
calcium entry blockers 313
diethylene glycol (abst) 619
glycerol induced 22:S-113
hantavirus disease in Africa (abst) 603
hyperalimentation, amino acid 22:S-72
hyperkalemia, heart transplantation (abst) 625
insulin metabolism 22:S-104
ischemic, ANP infusion (abst) 436
leukocyte proteinases 22:S-100
malarial origin in human kala-azar (abst) 606
malnutrition 22:S-167
mercury induced 246
prostacyclin on postischemic 479
proteases, catabolic factors in 22:S-94
protein prior to renal ischemia 22:S-76
solute transport in CAPD, new treatment 562
Acute tubular necrosis, CyA (abst) 625
Acute volume expansion, chloride 238
Adenosine
hypoxemia-induced decrease of GFR (abst) 437
Adenosine triphosphate
soluable 5'-nucleotidase (abst) 435
intracellular Ca (abst) 627
Adenylate cyclase
vasopressin-sensitive, subunit interactions 23:S-43
Adenylyl cyclase, G proteins 23:S-14
ADH
captopril inhibits hydroosmotic effect of 844
Adriamycin-induced nephropathy (abst) 627
Adult polycystic disease
DNA markers (abst) 772
intensive follow-up (abst) 774
mutations in the LDL gene 23:S-156
trimethoprim-sulfamethoxazole in cyst fluid 883
Age
results of regular dialysis (abst) 607
signal transduction of G proteins 23:S-38
Agonist, Ca signalling in cells 23S-68
Albumin
cationic in MCN 547
MCN, renal selectivity properties towards 69
Albuminuria
epithelial cell structure 736
Aldosterone
salt, volume and hypertension 590
Alkaline phosphatase, CyA (abst) 431
Alkalosis
isovolemic hemofiltration in dog 322
metabolic, antiacid and calcium polystyrene (abst) 437
Allografts
vascular lesions (abst) 432
Alpha adrenoceptor agonist
arterial hypotension in chronic hemodialysis 728
Alpha ketoanalogs, uremia 22:S-186
Aluminum
gastrointestinal absorption of, uremia 821
hemodialysis and hyperaluminemia 710
hydroxide, iron gastrointestinal absorption (abst) 622
phosphate binding (abst) 432
related osteomalacia, reverse osmosis 96
vitamin D_3 receptors, endorgan response 204
Alveolar gas exchange (abst) 620
Amiloride
molecular properties of action, Na transport targets 785
salt, volume and hypertension 590
Amino acid
abnormal metabolism in CRF 22:S-181
branched chain, catabolism and acidosis 808
CAPD, protein and energy levels 22:S-136
CRF and ketoacids 123
erythrocyte, plasma ammonium levels 22:S-197
growth hormone, induced acute rise in renal function ..... '82
hyperalimentation in ARF
insulin resistance, uremia
nutrition in hypertrophy of renal tissue 22:S-2
Sulfur, maintenance HD 22:S-191
Aminonucleoside nephrosis
dietary cholesterol supplementation 671
enhancement by administration of protamine 691
Ammonium levels
erythrocyte amino acids 22:S-197
Amyloid arthropathy, CRF (abst) 624
Amyloidosis and hydatid disease (abst) 608
AN-69 plate filter, HD (abst) 777
Analbuminemic rats, furosemide 198
Analysis, target, adenylate cyclase 23:S-43
Anaphylatoxin generation, blood cooling 907
Anaphylaxis, antigen responses 233
Anderson-Fabry's disease (abst) 437
Anemia
deferoxamine in HD (abst) 621
erythropoiesis, transplantation 526
hemodialysis and hyperaluminemia 710
HUS and TTP 292
in HD patients (abst) 614
Angiotensin
thirst and the renin- 21:S-27
Angiotensin converting enzyme
captopril, hydroosmotic effect of ADH 844
inhibition, reduction of proteinuria 78
ontogenesis of ACE 684

Angiotensin II
calcium in concentration (abst) 628
regulation of papillary plasma flow 472
thirst and the renin-angiotensin system 21:S-27
Anhydrosis, sweat secretion 21:S-102
Anion
exchange proteins in the kidney 23:S-129
transport 23:S-117
Anti-rat thymocyte serum, cell damage 514
Antibiotics
in cyst fluid from ADPKD kidneys 883
Antibodies
anticytoplasmatic, Wegener's granulomatosis (abst) 778
composition of crescents in human GN 284
down modulation of Heymann's nephritis, $HgCl_2$ 227
epithelial antigens, GBM (abst) 774
IgA nephropathy (abst) 426, 627
induced mesangial cell damage 514
monoclonal, immunosuppressants on T cell activation 362
monoclonal, T cells and macrophages in RPGN 868
polyclonal, sodium pump regulation 23:S-113
removal of subepithelial immune complexes 13
Anticoagulation, HD (abst) 622
Antidiuretic hormone
aging effect on vasopressin action 21:S-90
cellular events in vasopressin action 21:S-56
hyponatremia 21:S-67
Antidiuretic hormone
lithium clearance during natriuresis 376
morphological aspects of the action of 21:S-51
regulation of water metabolism in nephrotic children 21:S-83
removal during HF stimulates its secretion (abst) 428
water metabolism in historical perspectives 21:S-113
Antigen
β_2M significance in evaluation of renal function 635
fibrinolysis 280
mediated process, complement activation in IgA nephropathy 837
removal of subepithelial epithelial immune complexes 13
renal anaphylaxis in perfused kidney 233
Antiinflammatory drugs, prostaglandin 1
Antiporter
Na^+/H^+, genetic approach 23:S-144
Apolipoprotein profile in CRF 368
Arginine vasopressin
acetate relaxation 39
antagonists 21:S-76
Arterial calcification in ESRD 388
Arteriolar cell cultivation (abst) .....
Arterioles, afferent, ANF and renin 493
Ascites and cirrhosis (abst) 626
Asymmetric septal hypertrophy (abst) 626
Atherosclerosis
LDL receptor mutations 23:S-156
Atrial natriuretic factor
renin release in isolated afferent arterioles 493
Atrial natriuretic peptide
AII and PAF (abst) 628
catecholamines during ischemic ARF (abst) 436
cirrhosis (abst) 628
in renal failure, dialysate (abst) 434
indomethacin and sodium handling 774
ischemic ARF (abst) 436
mineralocorticoid or glucocorticoid excess (abst) 435
norepinephrine infusion (abst) 436
plasma levels and dialysance in terminal renal failure 554
site of action in humans 537
sodium handling of essential hypertension (abst) 773
Atriopeptides and cGMP (abst) 626
Autoimmune tubulointerstitial nephritis
induction, characterization 642
Azathioprine
anti-lymphocyte globulin, transplantation (abst) 610
CyA, graft histology (abst) 777
Azotemia
vitamin B-6 deficiency 22:S-162
diuretic-induced 47
loop diuretics in CRI 572
renal handling of urea 721

Backflux of H^+, tubular epithelium 136
Bacterial clearance in renal failure 678
Bacteriuria
in Algiers (abst) 604
in Ismailia (abst) 608
Bartter's syndrome
diluting segment reabsorption (abst) 773
Basement membrane proteoglycans 498
Basement membranes in cystic disease 187
Bence Jones protein toxicity 850
Beta blocker
CAPD (abst) 618
no antihypertensive effect (abst) 775
Beta$_2$-adrenergic receptor
homology with rhodopsin 23:S-2
Beta$_2$-microglobulin
significance in evaluation of renal function 635
Bicarbonate
acetate in hemodialysis 39
reabsorption, metabolic alkalosis, hemofiltration 322
Binding, Na,K,Cl-cotransport system 23:S-134
Biopsy
epidemiology of idiopathic glomerular disease 112
schistosoma hematobium infections in children (abst) 607
Biosynthesis, vasopressin 21:S-8
Blood
cooling effect on anaphylatoxin generation 907
flow, metabolic transport 22:S-9
gas, cuprophan reuse 117
hemodialysis ineffective in coagulation defects (abst) 606
peripheral morphology diagnosis of rejection (abst) 603
Blood pressure
ACE inhibition, proteinuria 78
dietary lipids in subtotal nephrectomy 335
exercise ameliorates PGN 815
K influence on 22:S-242
salt, volume and hypertension 590
sodium sensitivity and resistance 22:S-234
Blood-membrane, hemodialysis, cytokine 84
Bone
acidosis and BCAA catabolism 808
Al accumulation in uremics (abst) 620

Al related osteomalacia, reverse osmosis 96
alkaline phosphatase in patients on CyA (abst) 431
calcitriol treatment for osteodystrophy in children 89
keto acid supplements, nutrition, uremic patients.... S-170
marrow, IgA nephropathy (abst)..... 774
microanalytic study (abst)..... 611
vitamin D and renal osteodystrophy..... 911
vitamin D and skeletal resistance to PTH..... 801
Brain mechanisms and drinking 21:S-35
Brush border membrane, cations (abst).....
Bumetanide
furosemide, loop diuretics in CRI..... 572
binding, Na,K,Cl-cotransport 23:S-134, S-141

C-terminus peptides, synthetic 23:S-162
Cadmium poisoning, β_2M 635
Calcification microanalysis (abst).....
Calcification, arterial in ESRD 388
Calcitonin
calcium regulating hormones and the kidney 760
Calcitriol
high dose controls osteodystrophy in children..... 89
Calcium
adenosine and intracellular (abst) 627
AII and cultured glomerular mesangial cells (abst) 628
defects in hypertension, PTH (1–34)..... 22:S-249
ischemic ARF 313
Mg^{++} inhibits stones(abst)..... 603
oxalate stone disease, GFR..... 749
phosphate vitamin D and PTH in uremics (abst) 619
regulating hormones and the kidney..... 760
signalling in cells..... 23:S-68
vitamin D and renal osteodystrophy..... 911
vitamin D and skeletal resistance to PTH..... 801
cAMP
β_2-adreneric structure and function 23:S-8
cellular events in vassopressin action..... 21:S-56
Cancer
tumoral factors on cAMP production, transport (abst)..... 435
nitrosodimethylamine in CRF 22:S-159
CAPD
Algerian experience (abst)..... 604
alternative: 3 exchanges/day (abst)..... 615
betablockers (abst)..... 618
β_2-microglobulin effect on (abst)..... 432
ceftriazone (abst)..... 438
circulating maltose, isomaltose 22:S-210
diabetics (abst)..... 618
in Algiers (abst)..... 608
multicenter registry (abst)..... 622
peritoneal cavity lymphatic absorption..... 165
peritoneal effluent (abst) 618
protein, amino acids, energy levels in 22:S-136
serum magnesium level and arterial calcification in ESRD..... 388
solute transport, new treatment for ARF 562
technical developments (abst)..... 432
vs. HD in diabetics (abst) 613
Captopril
ADH in CCT, hydroosmotic effect..... 844
CEI and progressive GN..... 794
diabetic nephropathy (abst)..... 776
GFR, blood flow in essential hypertension (abst)..... 614
Carbohydrate
receptors, glycoprotein endocytosis 23:S-167
Cardiac
function, HD vs. HF..... 399
hypertrophy, secondary hyperparathyroidism, hemodialysis..... 899
Cardiovascular
effects in HD (abst) 620
molecular properties of amiloride action..... 785
vasopressin antagonists..... 21:S-76
pre-eclampsia in pregnancy, case study 151
Carnitine
L-carnitine in CRF 22:S-132
metabolism, CRF..... 22:S-116
precursor 6-N-trimethyllysine, HD..... 22:S-128
Carpal tunnel syndrome
hemodialysis (abst)..... 427, 617
Catabolism, protein regulation 22:S-81
Catecholamine
in CRF patients on HD 427
secretion, hypertension 590
Cathepsin B and L, nephrosis..... 354
Cation
albumin in MCN 547
organic in BBMV (abst)..... 435
transport in erythrocytes from uremic patients 256
Caval constriction, saline infusions 488
Cavity lymphatic absorption in dialysis 165
cDNA, anion transport 23:S-117
Ceftriazone in CAPD (abst) .....
Cell
calcium signalling in 23:S-68
growth, proximal tubule 23:S-61
organismic homeostasis..... 23:S-97
Children
ACE distribution 684
growth, CRF before and after transplantation (abst)..... 438
high dose calcitriol in osteodystrophy 89
hormonal regulation of water metabolism, nephrotic 21:S-83
mesangial changes in IgA nephropathy..... 585
Chloride
GFR in acute volume expansion..... 238
metabolic alkalosis, isovolemic hemofiltration 322
Cholesterol
LDL receptor mutations 23:S-156
supplementation, nephrosis..... 671
Chronic kidney disease in Turkey (abst) 604
Chronic renal failure
abnormal amino acid metabolism 22:S-181
after nephrotoxic nephritis 173
anemia, L-carnitine and sodium transport 754
apolipoprotein profile in patients..... 368
BCAA and acidosis, azotemia..... 808
carnitine metabolism 22:S-116
causes, presentation and outcome in Khartoum (abst)..... 608
circulating maltose, isomaltose 22:S-210
desferoxamine induced neurotoxicity (abst) 624
diabetes control and 22:S-53
dietary protein restriction and..... 22:S-49
fasting, fatty acid utilization in uremia 22:S-145
gastric flora and emptying rate (abst) 606
growth in children (abst) 438

ketoacid treatment following amino acids 123
ketoacids, low protein diet, CRF progression 22:S-67
L-carnitine supplementation 22:S-132
leukocyte proteinases, catabolism of ARF 22:S-100
nitrosodimethylamine modulation 22:S-159
rate of progression in 167 cases (abst) 429
serum apolipoprotein profile 368
serum thyroid hormones (abst) 605
skeletal resistance to PTH in CRF 801
Thick ascending limb, GFR and kidney mass 22:S-57
uremia, hypercoagulable (abst) 615
Chronic renal insufficiency
comparison of loop diuretics 572
protein loading and GFR 22:S-25
retarding progression of renal disease 22:S-35
solitary kidney, protein and GFR 22:S-29
Circulation
^{99}mTC-MAG3, plasma flow (abst) 775
computer modeling (abst) 433
papillary plasma flow, AII 472
Cirrhosis
and ascites, countertransport (abst) 626
ANP, glomerular contraction (abst) 628
GFR after protein loading S-32
Clearance, inulin and PAH (abst) 437
Climate, fluid and electrolyte balance 21:S-97
Cloning
β_2-adrenergic receptor 23:S-2
band 3 related cDNAs from kidney 23:S-117
G protein, signal transduction 23:S-14
Complement
activation, IgA nephropathy 837
Concentrating mechanism, renal 21:S-43
Concentration of urine, hot climate 21:S-97
Congestive heart failure
captopril and hydroosmotic effect of ADH 844
Converting enzyme inhibition
progressive GN in rat 794
Cortex
arteriolar smooth muscle cells from, cultivation (abst) 428
Cortical collecting tubule
captopril, hydroosmotic effect of ADH 844
H^+ secretion 136
Corticotropin releasing factor, thirst 21:S-14
Creatinine
Algiers survey, body size and excretion of (abst) 605
Crescentic glomerulonephritis 408
Crescents
composition in human glomerulonephritis 284
GN and lung purpura 408
Cuprophan
induced anaphylatoxin generation, blood cooling 907
reuse, lung diffusion capacity 117
reuse and pulmonary function (abst) 777
Cyclophosphamide in MGN 579
Cyclosporine
blood levels, function of graft (abst) 438
blood transfusions and HLA in transplantation (abst) 625
erythropoiesis following renal transplantation 526
G in transplantation (abst) 431
glomerular hemodynamics, hormonal participation 19
graft histology, AZA (abst) 777
in minimal change nephrotic syndrome (abst) 614
interactions with other drugs (abst) 610
kidney transplantation in Egypt (abst) 604
OKT3 mediated T cell activation 362
pancreas transplantation (abst) 619
platelet aggregation 888
switch to AZA after transplantation (abst) 435
three years use in transplantation (abst) 618
Cyst
endotoxin provocation in experimental cystic disease 329
glomerulosclerosis in mice transgenic for SV40 827
trimethoprim-sulfamethoxazole in fluid, ADPKD 883
viscoelastic properties of basement membranes in disease 187
Cystic fibrosis
transport processes in eccrine sweat gland 21:S-109
Cystic renal disease
glomerulosclerosis, SV40 827
Cytokine, hemodialysis, blood-membrane 84

DDAVP in uremic trombopathy (abst) 623
Deferoxamine
HD with anemia (abst) 621
Dehydration
brain mechanisms 21:S-35
fluid and electrolyte balance in hot climate 21:S-97
Desensitization, β_2-adrenergic receptor 23:S-2
Dexamethasone, hypertension 590
Diabetes
CAPD vs. HD (abst) 613
CAPD, 3 systems (abst) 618
control, effect on progression of renal failure 22:S-53
estimation of mean glomerular volume 929
hyperglycemia, glycosuria 895
hypocalcemia (abst) 615
insulin effect on sodium, water handling (abst) 605
integrated treatment with dialysis (abst) 613
nephropathy, captopril and ambuminuria (abst) 776
non-enzymatic glycation, altered renal structure 664
renal transplantation (abst) 612
retarding the progression of renal disease 22:S-35
Diabetes insipidus
distal tubular acidosis in nephritis (abst) 427
Diabetes mellitus
apolipoprotein profile of CRF patients 368
glomerular epithelial cell structure 736
Dialysate
bicarbonate, weight gain during HD 22:S-174
composition during HD 129
composition, intercompartmental fluid shift 267
Dialysis
anemia corrected by erythropoietin (abst) 427
asymmetric septal hypertrophy (abst) 626
blood cooling on anaphylatoxin generation 907
calcitonin and hyperparathyroidism (abst) 621
CAPD in Algiers (abst) 608
CAPD technical developments (abst) 432
CAPD, refractory congestive heart failure (abst) 426
cation transport in erythrocytes from uremics 256
computer modeling (abst) 433
eosinophilia (abst) 626
eriarticular erosions of hand skeleton (abst) 434
gastrointestinal absorption of Al 821
hepatitis B vaccine (abst) 429
IgE antigodies to isocyanates (abst) 429

integrated treatment, diabetic patients (abst) 613
L-carnitine effect on sodium transport 754
LAV/HTL VIII antibodies in transplantation (abst) 611
lymphatics, ultrafiltration in peritoneal 219
neoplasms, time (abst) 610
paired filtration, two chamber technique (abst) 613
peritonealcavity lymphatic absorption 165
polyvalent system (abst) 607
secondary hyperparathyroidism and cardiac hypertrophy 899
treatment in elderly (abst) 607
Dialyzer
ANP in terminal renal failure 554
modulation of leukopenia, thrombocytopenia (abst) 434
Diclofenac treatment, MGN (abst) .....
Diet
BCAA in uremia 808
branched-chain alpha ketoanalogs in uremics 22:S-186
cholesterol supplementation, aminonucleoside nephrosis 671
cirrhotics, GFR after protein loading 22:S-32
CRF after nephrotoxic nephritis 173
eicosanoids in experimental GN 22:S-40
erythrocyte insulin receptors, uremia 22:S-202
fasting, fatty acid utilization in uremia 22:S-145
fish oil and renal insufficiency 700
GFR, protein loading, patient with solitary kidney . 22:S-29
glucose metabolism in uremia 22:S-206
growth hormone effect on GFR and renal plasma flow 22:S-21
hypercalciuria in infancy (abst) 611
hypertension in obesity 22:S-254
idiopathic renal stone disease, vitamin D3 434
keto acid supplements, bone metabolism, uremia . 22:S-170
lipids in subtotal nephrectomy 335
ketoacids, low protein, CRF progression 22:S-67
Na and K intake in Egypt (abst) 604
protein loading and GFR 22:S-25
protein prior to renal ischemia 22:S-76
renal failure and protein restriction 22:S-49
retarding progression of renal disease 22:S-35
statistical selection of nutritional parameters 22:S-178
uremic toxicity and protein 22:S-62
Diethylene glycol, ARF (abst) 619
Diffuse proliferative glomerulonephritis
prognosis of segmental GN in SLE 274
Dinitrophenol IgE, anaphylaxis 233
Diuretic
amiloride action and Na transporting targets 785
comparison of loop, CRI 572
therapy, azotemia, urea appearance rate 47
DNA markers, APKD (abst) 772
Donor
complications, renal function in (abst) 627
cross match (abst) 617
unilateral nephrectomy in humans 714
Dopamine
metoclopramide and renal disease (abst) 778
Drinking and brain mechanisms 21:S-35

Eccrine sweating, physiology 21:S-102
Eicosanoid
role in experimental GN 22:S-40
synthesis, prostaglandin 1
Eicosapentaenoic acid, CRI 700
Elastase release in dialysis (abst) 613
Electrolyte
fluid balance in hot climates 21:S-97
fluid metabolism 21:S-93
transport processes in eccrine sweat gland 21:S-109
Embryogenesis, insulin receptor 23:S-61
Enalapril
hypertensive NIDDM patients (abst) 775
Encephalopathy
hemodialysis and hyperaluminemia 710
End-stage renal disease
bicarbonate HD, weight gain 22:S-174
enhancement of aminonucleoside nephrosis by protamine 691
experimental hypertsension and glomerulonephritis 652
peritoneal cavity lymphatic absorption 165
schistosomal specific nephropathy (abst) 605
segmental glomerulonephritis in SLE 274
serum and CSF trace elements in HD (abst) 604
serum magnesium level and arterial calcification 388
transplantation at Mansoura, Egypt (abst) 603
Endocarditis, infectious (abst) 623
Endocytic vesicles, non-clathrin coated 23:S162
Endocytosis
action of ADH 21:S-51
glycoprotein, membrane receptors that mediate 23:S-167
molecular sorting during 23:S-184
receptor mediated 23:S-162
Endopeptidase 24.11 in kinin metabolism 507
Endosomes during endocytosis 23:S-184
Endotoxin
provocation of experimental cystic disease 329
Entry blockers, Ca in ischemic ARF 313
Enzyme
glucocorticoids modulate receptors, Na-K ATPase activity 464
insulin action on protein synthesis 23:S-82
target analysis of vasopressin-sensitive adenylate cyclase 23:S-43
Epidemiology of glomerular disease 112
Epithelial cell
polyanion neutralization, prostanoid production 57
Erythrocytes
amino acid, plasma ammonium levels 22:S-197
cation transport, uremic patients 256
insulin receptors, uremia 22:S-202
HD (abst) 628
Erythroid band 3 anion transport 23:S-117
Erythropoiesis
correction of dialysis anemia by (abst) 427
dynamics after transplantation 526
transplantation, AZA, CyA and sandimmun (abst) 431
Essential hypertension
ANP and altered sodium handling (abst) 773
Essential mixed cryoglobulinemia (abst) 612
Eucaryotic cell, vasopressin 21:S-8
Evolution of water metabolism 21:S-113
Excretion
Algiers survey: body size and (abst) 605
mineraloxorticoids on urinary acid (abst) 432
Exercise
ameliorates progressive renal disease 815

fluid metabolism 21:S-93
glycerol induced ARF 22:S-113
Extrarenal epuration, salicylate (abst) 429

Factor H, absence in MPGN (abst) 616
Familial disease
Anderson-Fabry's disease (abst) 437
Fanconi's syndrome, β_2M 635
Fatty acids
thromboxane synthesis in platelets 62
Fibrin
composition of crescents in human GN 284
deposition of cross linked, in human kidney diseases 102
HUS and TTP, a single entity 292
procoagulant activity 31
Fibrinolysis, plasminogen activator 280
Fibrosis
interstitial during transplantation (abst) 437
Fine needle aspiration cytology (abst) 603
Fish oil and renal insufficiency 700
Fluid
body secretion, physiology of sweat 21:S-102
electrolyte balance in hot climates 21:S-97
homeostasis, brain mechanisms 21:S-35
metabolism in exercise 21:S-93
shift, dialysate composition 267
thirst 21:S-27
Focal segmental glomerulosclerosis
dietary cholesterol supplementation 671
hypertension (abst) 612
kidney graft, hyperfiltration (abst) 612
model by AMNS administration 691
reflux nephropathy 261
Fuel utilization, energy 22:S-9
Furosemide
analbuminemic rats and hypoalbuminemic patients 198
cation transport in erythrocytes from uremic patients 256
loop diuretics in CRI 572

G proteins, signal transduction 23:S-14
Gastric flora in CRF (abst) 606
Gastrointestinal absorption of Al 821
Gene
Na^+/H^+ antiporter 23:S-144
PEPCK and insulin action 23:S-82
vasopressin biosynthesis 21:S-8
Gliadin, antibodies (abst) 426
Glomerular basement membrane
albumin in MCN 69
antigenicity in hereditary nephritis (abst) 428
thickening, diabetic nephropathy 664
antibodies to epithelial antigens 774
removal of subepithelial immune complexes 13
Glomerular deposition for XFb 102
Glomerular disease
epidemiology of idiopathic 112
Glomerular filtration rate
acute protein load effect on 22:S-25
adenosine, hypoxemia-induced decrease in (abst) 437
azotemia 721
chloride in volume expansion 238
cirrhotics, protein loading 22:S-32
estimation of mean glomerular volume in diabetes 929
exercise ameliorates progressive renal disease 815
hypercalciuria in primary struvite nephrolithiasis 749
hyperglycemia and glycosuria 895
hypertonic saline infusions, thoracic caval constriction 488
metabolic alkalosis, isovolemic hemofiltration 322
oral protein load in patients with solitary kidney 22:S-29
site of action of ANP in humans 537
TAL, urine concentrating mechanism, kidney mass 22:S-57
tubuloglomerular feedback, partial ureteral occlusion 212
Glomerulonephritis
crescents composition 284
eicosanoids role in 22:S-40
experimental hypertension 652
human, monoclonal antibody analysis (abst) 622
rapidly progressive, T cells and macrophages 868
Glomerulopressin, growth hormone 22:S-21
Glomerulosclerosis
renal cysts in mice, SV40 827
Glomerulus
human, fatty acids stimulate platelet TXB_2 62
maturation of, basement membrane peoteoglycans 498
Glucose metabolism 22:S-206
Glucocorticoid
modulate renal glucocorticoid receptors 464
Gluconeogenesis
in liver and kidney 23:S-94
renal fuel utilization 22:S-9
Glycoprotein
endocytosis 23:S-167
sodium pump mechanism 23:S-97
Glycosuria, hyperglycemia 895
Goodpasture's syndrome
lung purpura with RPGN 408
Gordon's syndrome (abst) 776
Growth
polypeptide growth factors, Na^+/H^+ antiporter 23:S-144
Growth factor
Na^+/H^+ antiporter, genetic approach 144
unilateral nephrectomy in humans 714
Growth hormone
amino acid induced acute rise in renal function 382
effect on GFR and renal plasma flow 22:S-21
Guanosine monophosphate, RF (abst) 436

Halides, H_2O_2 action in IC GN 342
Hantavirus disease
Africa (abst) 603
Belgium (abst) 774
Heart disease, hemodialysis (abst) 616
Heart failure, CAPD treatment (abst) 426
Heat, fluid metabolism in exercise 21:S-93
Hemodiafiltration
HD compared 399
paired filtration with two chamber technique (abst) 613
Hemodialysis
acetate relaxation of isolated smooth muscle 39
alveolar gas exchange (abst) 620
amyloid arthropathy, CRF (abst) 624
anemia, DFO (abst) 614
ANP in terminal renal failure 554

antiacid and calcium polystyrene (abst) 437
arterial hypotension 728
autonomic nervous system (abst) 618
beta $_2$ microglobulin (abst) 432
bicarbonate, weight gain 22:S-174
blood cooling effect on anaphylatoxin generation 907
blood-membrane in, cytokine 84
calcium carbonate and calcium gluconate and binder (abst) 436
CAPD in Algeria (abst) 604
cardiac function 399
cardiovascular effects (abst) 620
carnitine, 6-N-Trimethyllysine and 22:S-128
carpal tunnel syndrome (abst) 427
carpal tunnel syndrome with amyloids (abst) 617
catecholamines in patients with CRF (abst) 427
cationic fluxes in erythrocytes (abst) 628
cuprophan reuse 117
dialysate composition, fluid shift 267
dialysate compositon change 129
elastase release (abst) 613
gastrointestinal absorption of Al 821
hemoglobin stabilization buffer capacity (abst) 608
hepatitis B vaccination, zinc, seroconversion rate 22:S-149
histamine release (abst) 427
HIV antibodies, transplantation (abst) 616
HTLV III antibodies (abst) 609
hyperaluminemia 710
ineffective in correction of blood coagulation (abst) 606
ischemic heart disease (abst) 616
L-carnitine supplementation, CRF 22:S-132
lipid metabolism of heparin treatment (abst) 433
maintenance, sulfur amino acids 22:S-191
membranes, PAF-acether (abst) 614
metabolic alkalosis, antiacid and calcium polystyrene (abst) 437
middle molecule removal (abst) 621
multicenter CAPD registry (abst) 622
nutritional 22:S-167
osteomalacia in uremics (abst) 623
polyvalent system (abst) 607
proteases, catabolic factors in RF 22:S-94
secondary hyperparathyroidism and cardiac hypertrophy 899
serum and CSF trace elements in ESRD (abst) 604
serum phosphate and Al phosphate binders (abst) 609
statistical selection, nutritional parameters 22:S-178
symptomatic hypotension (abst) 616
thirst regulation (abst) 620
tissue plasminogen activator, fibrinolysis 280
without anticoagulation (abst) 622

Hemodialyzer
extracorporeal enzymatic heparin removal 452

Hemodynamics
ANF on renin release 493
dialysate composition, intercompartmental fluid shift 267
mercury induced ARF 246
papillary plasma flow and AII 472
regulation of renal, amino acid and hormone 22:S-15
semichronic hypoproteinemia (abst) 776
water loading (abst) 776

Hemofiltration
ADH removal during HF stimulates its secretion (abst) 428
AN-69 plate filter (abst) 777
metabolic alkalosis in isovolemic 322

Hemoglobin stabilization in HD (abst) 608

Hemolytic uremic syndrome
CyA enhances platelet aggregation 888
TTP 292

Heparin
basement membrane proteoglycans and maturation of glomerulus 498
blood picture and lipoproteins (abst) 433
coagulation inhibitors in nephrotic syndrome (abst) 619
extracorporeal enzymatic removal 452
treatment in HD (abst) 433

Hepatic fibrosis, schistosomal GN (abst) 605

Hepatitis
hemodialysis, after transplantation (abst) 616
vaccine in dialysis (abst) 429

Hepatocytes, O_2 and methyguanidine 22:S-229

Heymann's nephritis
down modulation by mercuric chloride 227

Histamine release during HD (abst) 427

Homeostasis
vasopressin antagonists 21:S-76

Hormone
action of ADH in transport 21:S-51
calcium regulating 760
calcium signalling 23:S-68
G proteins, signal transduction 23:S-14
effects on binding sites 23:S-141
growth, amino acids and rise in renal function 382
growth, effect on GFR and renal plasma flow 22:S-21
insulin action on protein synthesis 23S-82
peptide, vasopressin 21:S-8
PTH, renal and hepatic uptake 22:S-221
receptor interactions 23:S-56
receptor, β_2-adrenergic structure and function 23:S-2
regulation of hemodynamics, amino acid, hormones 22:15
regulation of water metabolism, nephrotic children 21:S-83
serum thyroid, chronic renal failure (abst) 605
signal transduction of G proteins 23:S-38
thirst, renin-angiotensin system 21:S-27
thyroid, and renal transport 443
vasopressin-sensitive adenylate cyclase 23:S-43
vitamin D and renal osteodystrophy 911
water metabolism in historical perspectives 21:S-113

Hydatid disease, amyloidosis (abst) 608

Hydration
dehydration, brain mechanisms 21:S-35
vasopressin antagonists 21:S-76

Hydrocortisone
modulation of glucocorticoid receptors 464

Hydrogen ion secretion in tubules 136

Hydrolysis, 5′-nucleotidase (abst) 435

Hydronephrosis, tubuloglomerular 212

Hydroosmosis
cellular events in vasopressin 21:S-56

Hydrostatic properties in cystic disease 187

Hyperalbuminemia
and PTH (abst) 629

HD patients 710
Hyperalimentation, amino acid, ARF 22:S-72
Hypercalcemia
vitamin D and renal osteodystrophy 911
vitamin D_3 and aluminum intoxication 204
Hypercalciuria
GFR and primary struvite nephrolithiasis 749
idiopathic in infancy (abst) 611
struvite nephrolithiasis 749
Hyperfiltration
FSGS in kidney graft (abst) 612
proteinuria in FH rats (abst) 772
reflux nephropathy 261
Hyperglycemia
control of diabetes, progression of renal disease ... 22:S-53
diabetes 664
glycosuria, inulin and para-amino hippurate clearance 895
insulin metabolism in ARF 22:S-109
Hyperkalemia
renal failure (abst) 623
Hypermagnesemia, arterial calcifications 388
Hyperosmolar
syndrome, thirst and renin-angiotensin system 21:S-27
Hyperparathyroidism
secondary, cardiac hypertrophy in hemodialysis patients 899
Hyperphosphatemia in uremia 22:S-215
Hypertension
CEI and progressive GN in rat 794
dietary sodium (abst) 432
endopeptidase 24.11 in kinin metabolism 507
essential, captopril (abst) 614
exercise, metabolic response to, dialysis 876
experimental, and glomerulonephritis 652
FSGS (abst) 612
Gordon's syndrome (abst) 776
hyperfiltration and proteinuria in FH rats (abst) 772
malignant (abst) 612
NIDDM, enalapril (abst) 775
nisoldipine (abst) 614
obesity 22:254
potassium influence on BP 22:S-242
pregnancy, case report 151
proteinuria, solitary kidneys (abst) 611
salt, volume: causation or correlation 590
Hypertonic hemodialysis (abst) .....
Hypertrophy
exercise ameliorates progressive GN 815
hormone receptor interactions 23:S-61
nutrition role in renal disease 22:S-2
reflux nephropathy 261
unilateral nephrectomy in humans 714
Hypoalbuminemic, furosemide 198
Hypocalcemia
calcium regulating hormones and the kidney 760
CRF, skeletal resistance to PTH 801
diabetics, PTH and bone (abst) 615
PTH, vitamin D axis, unexplained 22:S-225
Hypocitraturia
oxalocalcic renal lithiasis (abst) 629
Hyponatremia 21:S-67
hormonal regulation of water metabolism 21:S-83
Hypophosphatemia
rickets in Kenyan children (abst) 605
Hypoproteinemia, semichronic (abst) 776
Hypotension
arterial, in chronic hemodialysis 728
dialysis induced, mannitol and saline alleviates (abst) 607
extracorporeal enzymatic heparin removal 452
Hypothalamus
axis in uremia (abst) 620
sweat secretion 21:S-102
Hypothyroid animals and renal transport 443
Hypoxemia
adenosine, GFR (abst) 437
pulmonary dysfunction 117

Idiopathic calcium urolithiasis (abst) 629
Idiopathic glomerular disease 112
Idiopathic nephrotic syndrome
β_2M in lymphocyte culture supernatants (abst) 426
IgA nephropathy
bone marrow (abst) 774
complement activation, antigen mediated 837
detection of shared idiotypes (abst) 627
immune regulation, lymphocytes (abst) 627
immunological studies in six familial nephropathy (abst) 628
mesangial changes in nephropathy in children 585
IgE
antibodies in dialysis (abst) 429
anti-etilen oxide, dialysis eosinophilia (abst) 626
renal anaphylaxis, antigen initiated responses 233
IgG
clearance, systemic lupus erythematosus (abst) 777
Immune complex
clearance kinetics in s. mansoni (abst) 605
myeloperoxidase-H_2O_2 halide system 342
removal of, unaltered or cationic antigen 13
T cells and macrophages in RPGN 868
Immune system
T cells and macrophages in RPGN 868
Immunity
autoimmune tubulointerstitial nephritis 642
TIN in LEW rats 642
Immunogenetics of MGN (abst) 606
Immunology
epidemiology of idiopathic glomerular disease 112
familial IgA nephropathies (abst) 628
glomerular podocytic processes 742
Immunosuppression
cyclosporine, glomerular hemodynamics 19
erythropoiesis 526
low doses of drugs in transplantation (abst) 610
mercuric chloride in Heymann's nephritis 227
T cell activation 362
Indomethacin
sodium balance and ANP 774
treatment of renal colic (abst) 604
Infection
β_2M 635
reflux nephropathy 261
Infectious endocarditis (abst) 623
Inflammation
bacterial clearance in renal failure 678
Injury
amino acid hyperalimentation in ARF 22:S-72
antibody-induced mesangial cell damage 514

chronic aminonucleoside nephrosis ... 671
complement activation in IgAN, antigen ... 837
glomerular, myeloperoxidase-H_2O_2-halide system ... 342
ischemia, calcium ... 313
prognosis of segmental glomerulonephritis in SLE ... 274
protein overload proteinuria (abst) ... 772
Inositol trisphosphate, Ca signalling ... 23:S-68
Insulin
gluconeogenesis ... 23:S-94
hormone receptor interactions ... 23:S-56
metabolism in ARF ... 22:S-109
protein synthesis ... 23:S-82
receptors, hormone receptor interactions ... 23:S-61
sodium and water handling in insulinopenic diabetics (abst) ... 605
Intercompartmental fluid shift ... 267
Interleukin
blood-membrane in hemodialysis ... 84
uremic lymphoblastogenesis (abst) ... 621
Interstitial nephritis
diabetes (abst) ... 427
drug induced (abst) ... 610
Intoxication
Al and vitamin D ... 204
salicylate, ERE (abst) ... 429
Inulin
clearance, hyperglycemia ... 895
PAH clearances, measurements (abst) ... 437
Iron gastrointestinal absorption (abst) ... 622
Ischemia
cellular Ca, entry blockers ... 313
loss of polarity, Na,K,ATPase in apical membrane ... 23:S-208
prostacyclin in ARF ... 479
protein prior to renal ... 22:S-76

Kala-azar and GN (abst) ... 606
Kallikrein
micropuncture localization in rat nephron ... 26
Ketanserin and RBF (abst) ... 778
Ketoacids
CRF following amino acids ... 123
Kinase C, Na^+/H^+ antiporter ... 23:S-150
Kinin
metabolism, endopeptidase 24.11 ... 507

L-carnitine
sodium transport in dialyzed uremic patients ... 754
Lesion
acute vascular, in renal allografts (abst) ... 432
glomerulosclerosis and renal cysts, SV40 ... 827
prognosis of segmental GN in SLE ... 274
Leukocytes
endotoxin in renal cystic disease ... 329
proteinases, catabolism of ARF ... 22:S-100
Leukopenia
dialyzer membranes (abst) ... 434
Lipid
dietary, effect in subtotal nephrectomy ... 335
move from apical to basolateral surfaces ... 23:S-208
transplantation (abst) ... 617
Lipopolysaccharide, procoagulant in ... 31
Lipoprotein
apolipoprotein profile of patients with CRF ... 368
heparine on blood picture (abst) ... 433
Lisinopril on blood pressure ... 78
Lithium
clearance during natriuresis ... 376
sodium clearance (abst) ... 777
Loop diuretics in CRI ... 572
Loop of Henle
renal concentrating mechanism ... 21:S-43
Low density lipoprotein receptor ... 23:S-156
Lung purpura, crescentic GN ... 408
Lung, diffusion capacity in hemodialysis ... 117
Lupus erythematosus
IgG clearance (abst) ... 777
prognosis of segmental glomerulonephritis ... 274
Lupus nephritis
plasma exchange (abst) ... 433
Lymphatic absorption, dialysis ... 165
Lymphatics
ultrafiltration, peritoneal dialysis ... 219
Lymphoblastogenesis
IL-2 (abst) ... 621
uremia (abst) ... 621
Lymphocyte
β_2M in lymphocyte culture supernatants (abst) ... 426
IgA immune regulation (abst) ... 627
rejection (abst) ... 615
Lysis
cellular handling of water ... 21:S-2
Lysosomal
system, proteolytic capacity ... 354

Macrophages, T cells in RPGN ... 868
Magnesium
GTP levels in the cell ... 23:S-38
osteodystrophy (abst) ... 777
serum level and arterial calcification in ESRD ... 388
Malignant hypertension (abst) ... 612
Mannitol
saline alleviates hypotension (abst) ... 607
Mean glomerular volume in diabetes ... 929
Medulla
renal concentrating mechanism ... 21:S-43
Membrane glycoproteins, Na pump ... 23:S-97
Membranoproliferative glomerulonephritis
factor H absence (abst) ... 616
Membranous glomerulonephritis
complement C4 phenotypes (abst) ... 606
cyclophosphamide ... 579
diclofenac treatment (abst) ... 428
immunogenetics (abst) ... 606
Mercuric chloride
down modulation of Heymann's nephritis ... 227
Mercury induced renal failure ... 246
Mesangial cell damage, antibody-induced ... 514
Mesangial hypercellularity, IgA in child ... 585
Mesangialproliferative GN
sarcoidosis (abst) ... 438
Mesangio-capillary GN improvement (abst) ... 607
Messengers, intracellular ... 23:S-68
Metabolism
carnitine, CRF ... 22:S-116
control of diabetes, progression of renal disease ... 22:S-53
dialysate changes during HD ... 129
endopeptidase 24.11 in kinin ... 507
fuel utilization, energy requirements for kidngy ... 22:S-9
inhibition of prostaglandin synthesis ... 1

insulin, ARF 22:109
nitrosodimethylamine in CRF 22:S-159
regulation of renal hemodynamics 22:S-15
Methylguanidine synthesis
oxygen role in hepatocytes 22:S-229
Metoclopramide, renal disease (abst) .....
Microcytic anemia, Al in uremia 821
Middle molecule removal, HD (abst) 621
Mineralocorticoid
in urinary acid excretion in adrenalectomized rat (abst) 434
or glucocorticoid excess, ANP increased (abst) 435
urinary acid excretion (abst) 432
Minimal change disease
glomerular podocytic processes 742
Minimal change nephropathy
cationic albumin 547
cyclosporine in (abst) 614
endogenous albumin 69
Modeling adenylate cyclase 23:S-51
Monoclonal antibody
band 3 immunoreactivity 23:S-129
cross linked fibrin in human kidney diseases 102
human glomerulonephritis (abst) 622
Monocytes, crescents in human GN 284
Murine acute renal failure 246
Myeloma
Bence Jones protein toxicity in proximal tubule 850
Myeloperoxicase-H_2O_2-halide system 342

Na,K, ATPase
glucocorticoids modulate receptors 464
sodium pump in excitable cells 23:S-97
thyroid hormones and renal transport 443
Na,K,Cl-cotransport system 23:S-134
Natriuresis
effect of ANP 537
lithium clearance during hypotonic expansion 376
Neoplasms on dialysis patients (abst) 610
Neopterin blood levels in RT (abst) 611
Nephrectomy
unilateral in humans 714
Nephritis
autoantibody formation complicating schistosomiasis (abst) 603
CRF after nephrotoxic 173
drug induced acute tubulointerstitial (abst) 612
hereditary, antigenicity of GBM (abst) 428
interstitial, drug induced (abst) 610
lupus, plasma exchange (abst) 433
nephrotoxic, CRF after 173
Nephrocalcinosis (abst) 428
Nephrolithiasis, climate 21:S-97
Nephron
function and renal hemodynamic, ACE 684
localization of kallikrein secretion in rat 26
site of action of ANP in humans 537
Nephropathy
adriamycin-induced (abst) 627
reflux, morphometric aspects 261
sickle cell (abst) 608
Nephrosis
puromycin aminonucleoside, cathepsin B and L 354
Nephrotic syndrome
children, hormonal regulation of water metabolism 21:S-83
coagulation inhibitors (abst) 619
cyclophosphamide in MGN 579
prednisolone, glomerular permeability (abst) 772
tropical disease associations (abst) 605
Nephrotoxicity
amino acid hyperalimentation in ARF 22:S-72
CyA enhances platelet aggregation 888
cyclosporine, glomerular hemodynamics 19
endotoxin in renal cystic disease 329
erythropoiesis after transplantation 526
exercise ameliorates progressive renal disease 815
Nervous system
calcium signalling in cells 23:S-68
hemodialysis (abst) 618
Neuron
sodium pump regulation 23:S113
vasopressin and thirst 21:S-14
Neurotoxicity, desferoxamine (abst) 624
Neurotransmitter, calcium signalling 23:S-68
Neutralization of surface charge
polyanion 57
Nifedipine, renal toxicity (abst) 614
Nisoldipine, hypertension (abst) 614
Nitrogen
restriction, muscle protein synthesis, uremic 22:S-153
Nitrosodimethylamine, CRF 22:S-159
Nonapeptide, vasopressin biosynthesis 21:S-8
Norepinephrine
ANP during infusion (abst) 436
NSAD, prostaglandin inhibition 1
Nutrition
CRF, ketoacids following amino acids 123
hypertrophy of renal disease 22:S-2

Obesity, hypertension 22:S-254
Occlusion, tubuloglomerular feedback 212
OKT3 T cell activation 362
Osmoregulation, ADH secretion 21:S-20
Osmosis
cellular handling of water 21:S-2
dialysate composition 267
renal concentrating mechanism 21:S-43
vasopressin biosynthesis 21:S-8
Osteocalcin levels in uremia (abst) 622
Osteodystrophy
children, high dose calcitriol 89
renal (abst) 623
serum magnesium and bone (abst) 777
vitamin D and renal 911
Osteomalacia
Al and vitamin D_3 receptors, endorgan response 204
aluminum related: reverse osmosis 96
gastrointestinal absorption of Al in uremia 821
hemodialysis and hyperaluminemia 710
uremics before dialysis (abst) 623
Oxalate nephropathy (abst) 428
Oxalocalcic renal lithiasis (abst) 629
Oxygen, metabolic transport 22:S-9

Pancreas transplantation CyA (abst) 619
Papillary plasma flow regulation, AII 472

Para-amino hippurate clearance
hyperglycemia ... 895
in HD (abst) ... 437
Parathyroid hormone
calcium regulating hormones and the kidney ... 760
calcium signalling ... 23:S-77
gastrointestinal absorption of Al in uremia ... 821
hepatic and renal uptake ... 22:S-221
hyperalbuminemia (abst) ... 629
PTH (1–34), Ca^{2+} defects in hypertension ... 22:S-249
vitamin D effect on skeletal resistance to ... 801
vitamin D_3 in uremia ... 350
PEPCK, insulin action on protein ... 23:S-82
Peptide
ACE distribution in fetus ... 684
basement membrane proteoglycans in glomerulus ... 498
thirst and vasopressin ... 21:S-14
vasopressin ... 21:S-8
Peritoneal dialysis
cavity lymphatic absorption ... 165
ultrafiltration, role of lymphatics ... 219
Peritoneal effluent in CAPD (abst) ... 618
pH
Na^+/H^+ antiporter, genetic approach ... 23:S-150
Phenotypes, complement C4 (abst) ... 606
Phosphate
binder in HD, calcium carbonate/gluconate (abst) ... 436
binder, calcium carbonate/gluconate in HD (abst) ... 436
binding in some products (abst) ... 432
hyperphosphatemia in uremia ... 22:S-215
serum, $Al(OH)_3$ binders (abst) ... 609
Phosphorus
vitamin D and renal osteodystrophy ... 911
Photolabelling, Na,K,Cl-cotransport ... 23:S-134
Pitts, Robert F, lecture ... 136
Pituitary gland
function, ADH secretion ... 21:S-20
thirst and vasopressin ... 21:S-14
Plasma
flow, effective renal (abst) ... 775
membrane, hormone receptor interactions ... 23:S-56
Plasmapheresis, rejection (abst) ... 280
Plasminogen activator, fibrinolysis ... 280
Platelet
cyclosporine A enhances aggregation ... 883
fatty acids and TXB_2 ... 62
in uremics (abst) ... 624
Platelet activating factor
AII, atrial natriuretic peptide (abst) ... 628
hemodialysis membranes (abst) ... 614
Podocytic processes, proteinuria ... 742
Polyanion neutralization, prostanoid ... 57
Polycystic kidney disease
glomerulosclerosis and renal cysts, mice
transgenic for SV40 ... 827
trimethoprim-sulfamethoxazole in cyst fluid ... 883
Polytetrafluoroethylene vascular grafts ... 395
Polyunsaturated fatty acids, CRI ... 700
Potassium
efflux in red cells, atriopeptides (abst) ... 626
influence on BP ... 22:S-242
Pre-eclamptic syndrome ... 151
Prednisolone
circulation, plasma renin activity and proteinuria
(abst) ... 775
glomerular permeability in nephrotics (abst) ... 772
safety, CyA in transplantation (abst) ... 617
Pregnancy
hypertension ... 151
Primary struvite nephrolithiasis
reduced glomerular filtration rate, hypercalciuria ... 749
Progressive glomerulosclerosis
converting enzyme inhibition ... 794
CRF after nephrotoxic nephritis ... 173
Progressive renal failure
essential mixed cryoglobulinemia (abst) ... 612
Proliferative glomerulonephritis
Egyption center experience (abst) ... 608
Prostacyclin
postischemic ARF ... 479
Prostaglandin
azotemia and normal renal function ... 721
dietary fish oil and renal insufficiency ... 700
E2 receptors, biochemical characterization ... 181
synthesis, inhibition of renal ... 1
Prostanoid
eicosanoids in experimental GN ... 22:S-40
production, polyanion ... 57
Protamine
aminonucleoside nephrosis ... 691
Protease in renal failure ... 22:S-94
Protein
abnormal amino acid metabolism ... 22:181
acute loading, effect on GFR ... 22:S-25
amino acids, hormones regulate hemodynamics ... 22:S-15
apical and basolateral in MDCK cells ... 23:S-201
band 3, anion transport ... 23:S-117
Bence Jones, toxicity ... 850
β_2-adrenergic receptor, homology with rhodopsin ... 23:S-2
CAPD patients, amino acids and energy levels ... 22:S-136
catabolism regulation ... 22:S-81
cationic albumin in MCN ... 547
dietary, prior to renal ischemia ... 22:S-76
G, signal transduction ... 23:S-14
growth hormone on GFR and renal plasma flow ... 22:S-21
increase in GFR and kidney mass ... 22:S-57
inhibition, CEI and progressive GN in rat ... 794
insulin and gene transcription ... 23:S-94
ketoacids, diet, CRF progression ... 22:S-67
kinase C, calcium signalling ... 23:S-77
LDL receptor mutations ... 23:S-156
loading, GFR in cirrhotics ... 22:S-32
malnutrition and hemodialysis ... 22:S-167
membrane traffic in MDCK cells ... 23:S-201
membrane, hormone receptor interactions ... 23:S-56
muscle, insulin resistance, amino acid supply ... 22:S-104
Na,K,Cl-cotransport system ... 23:S-134
nitrogen restriction, uremia ... 22:S-153
nutrition, hypertrophy of renal tissue ... 22:S-2
overload proteinuria (abst) ... 772
proteases, catabolic factors in RF ... 22:S-94
restriction and renal failure ... 22:S-49
retarding progression of renal disease ... S-35
sodium pump in excitable cells ... 23:S-97
synthesis, insulin action ... 23:S-82
thick ascending limb, GFR and kidney mass ... 22:S-57
uremic toxicity ... 22:S-62
Proteinuria
ACE inhibition ... 78
cathepsin B and L in PAN ... 354

cationic albumin in MCN 547
control of diabetes, progression of renal disease ... 22:S-53
converting enzyme inhibition and progressive GN..... 794
cyclophosphamide in MGN..... 579
glomerular epithelial cell structure, diabetes mellitus..... 736
hypertension in pregnancy..... 151
hypertension in solitary kidneys (abst)..... 611
mesangio-capillary GN (abst) 607
podocytic processes..... 742
pre-eclampsia, case report..... 151
prednisolone effect (abst)..... 775
Proteoglycan, basement membrane maturity 498
Proton pump
anion transport..... 23:S-129
endocytosis 23:S-196
Pulmonary, cuprophane reuse (abst) .....
Pulse methylprednisolone, RPGN, T cells..... 868
Pumpless dialysis technique and ARF 562
Puromycin aminonucleoside nephrosis..... 354
cholesterol 671
Pyelonephritis in Algiers (abst)..... 604

Radiation
adenylate cyclase in cells 23:S-43
inactivation 23:S-51
Radiopharmaceuticals in rats (abst) 775
Rapidly progressive glomerulonephritis
age, renal biopsy (abst)..... 426
immunopathogenesis of crescentic GN..... 408
Receptor
β_2-adrenergic, homology with rhodopsin 23:S-2
FcR transport, membrane protein, targeting to lysosomes..... 23:S-184
hormone receptor interactions 23:S-56
LDL, natural and synthetic mutations in 23:S-156
mediate glycoprotein endocytosis..... 23:S-167
PGE_2, biochemical characterization 181
Reflux nephropathy, morphometric aspects..... 261
Rejection
acute vascular, plasmapheresis (abst)..... 627
CyA enhances platelet aggregation 888
Renal colic (abst)..... 604
Renal failure
ANP, plasma levels and dialysance (abst) 434
causes, presentation and outcome in Khartoum (abst)..... 608
CRF in patients given ketoacids following amino acids 123
dietary lipids 335
HUS and TTP a single entity 292
hyperkalemia treatment (abst)..... 623
ischemic, dibutyryl cyclic guanosine monophosphate (abst)..... 436
mercury induced 246
PTH vitamin D_3 receptors in uremia..... 350
rate of progression in 167 cases (abst) 429
reflux nephropathy..... 261
Staphylococcus epidermidis 678
terminal and ANP 554
Renal insufficiency
vitamin D and renal osteodystrophy..... 911
Renal osteodystrophy (abst)..... .....
Renal parenchyma, TGF mechanism 217
Renal plasma flow
exercise ameliorates progressive renal disease..... 815
growth hormone effect on GFR and S-21
Renal stone disease
sodium content in (abst) 434
Renin
ANF in isolated afferent arterioles 493
Na sensitivity, resistance of BP 22:S-234
thirst, angiotensin system 21:S-27
Rhodopsin, β_2-adrenergic receptor..... 23:S-2
Rickets
biochemical parameters (abst)..... 605
osteodystrophy, vitamin D 911

S. mansoni, clearance kinetics (abst) 605
Saline
hypertonic infusions, thoracic caval constriction..... 488
Salt
volume and hypertension..... 590
Sarcoidosis, Mes PGN (abst) 438
Schistosoma hematobium infection (abst) 607
Schistosomal glomerulopathy
hepatic macrophage function (abst)..... 605
ESRD (abst)..... 605
Schistosomiasis
autoantibody 603
proliferative glomerulonephritis, Egypt (abst) 608
Sclerosis, reflux nephropathy 261
Secondary renal hyperparathyroidism 350
Secretion
ADH, physiology of 21:S-20
cellular handling of water 21:S-2
thirst and vasopressin 21:S-14
Segmental glomerulonephritis
prognosis in systemic lupus erythematosus 274
Serotonin
ketanserin and RBF (abst)..... 778
Sickle cell nephropathy (abst)..... 608
Signal
internal, endocytosis of glycoprotein 23:S-181
transduction, G proteins 23:S-14
transduction, Na^+/H^+ antiporter 144
Simian virus 40, cysts, GS 827
Skeleton, hand, dialysis (abst) 434
Sodium
depletion, urea appearance rate, azotemia 47
diluting segment reabsorption in Bartter's syndrome (abst)..... 773
familial hypertension (abst)..... 432
H^+ antiporter, genetic approach..... 23:S-144
hyponatremia..... 21:S-67
K intake in Egypt (abst) 604
lithium clearance (abst) 777
lithium clearance during natriuresis 376
Na,K,Cl-cotransport system 23:S-134
plasma contains transport stimulants (abst) 773
proton exchanger, Na/H antiporter..... 23:S-150
pump regulation in excitable cells..... 23:S-97
sensitivity, resistance of BP 22:S-234
transport target, amiloride action 785
Somatomedins, growth hormone 387
Staphylococcus epidermidis challenge 678
Stenoses, venous in grafts..... 395
Steroids, OKT3 mediated cell activation 362
Stones, Mg^{++} inhibits 603

Struvite nephrolithiasis, GFR 749
Surface polarity
lipid movement in basolateral, apical surfaces 23:S-208
SV40, GS and renal cysts in mice 827
Sweat
fluid metabolism in exercise 21:S-93
physiology of secretion 21:S-102
transport processes in eccrine 21:S-109
Symptomatic hypotension, HD (abst) .....

T cell
immunosuppressants on OKT3 associated 362
macrophages in RPGN 868
T-lymphocyte
subsets in uremics, tuberculous infections (abst) 606
Target analysis of adenylate cyclase 23:S-43
Thick ascending limb
urine concentrating mechanism, GFR 22:S-57
Thirst
aging, effect on vasopressin action 21:S-90
regulation in HD with CRF (abst) 620
renin-angiotensin system 21:S-27
vasopressin secretion 21:S-14
Thoracic caval constriction, saline 488
Thromboembolic phenomena, CyA, platelets 888
Thrombotic thrombocytopenic purpura, HUS 292
Thromboxane A2
CyA enhances platelet aggregation 888
fatty acids, synthesis in platelets 62
transplant recipients (abst) 615
Thrombus formation, heparin removal 452
Toxicity
Bence Jones protein, proximal tubule epithelium 850
blood cooling effect on anaphylatoxin generation 907
sublingual nifedipine prevents (abst) 614
uremic and protein diet 22:S-62
Toxin
enzymatic heparin removal in sheep model 452
fibrinolysis, tissue plasminogen activator in HD 280
Transcription, insulin and gene 23:S-94
Transduction, G proteins 23:S-14
Transmembrane ion fluxes 21:S-2
Transplant
liver function in stable patients (abst) 433
Transplantation
AZA and anti-lymphocyte globulin (abst) 610
AZA vs. CYA on erythropoiesis (abst) 431
beta blockers (abst) 775
blood transfusions, HLA (abst) 625
calcitonin and hyperparathyroidism (abst) 621
complications in donors (abst) 627
cross-match (abst) 617
CyA and acute tubular necrosis (abst) 625
CyA dosage on blood levels, survival (abst) 438
CyA in Cairo (abst) 604
CyA interactions with other drugs (abst) 610
CyA switch to AZA after (abst) 435
cyclosporine G (abst) 431
diabetic patients (abst) 612
erythropoiesis dynamics after 526
fine needle aspiration cytology (abst) 603
heart, ARF and hyperkalemia (abst) 625
hepatitis in hemodialysis (abst) 616
HIV antibodies and hemodialysis (abst) 616
HUS and TTP, variable expression of single entity 292
immunosuppressive efficacy of low dose drugs (abst) 610
in Turkey (abst) 604
interstitial fibrosis (abst) 437
LAV/HTLVIII antibodies dialysis (abst) 611
lipid metabolism (abst) 617
living related at Mansoura, Egypt (abst) 603
neopterin blood levels (abst) 611
peripheral blood morphology to diagnose rejection (abst) 603
safety to stop prednisone, CyA (abst) 617
statistical analysis of 174 (abst) 625
three years of cyclosporine (abst) 618
thromboxane A2 in renal (abst) 615
action of ADH 21:S-51
Transport
anion 23:S-117
captopril, ADH effect on CCT 844
cellular events in vasopressin 21:S-56
epithelium cells, plasma membrane components .. 23:S-201
fuel utilization, energy requirements 22:S-9
intracellualr, membrane ligands and receptors, endocytosis 23:S-184
Na,K,Cl-cotransport system 23:S-134
organic cations in BBMV (abst) 435
PGE receptors, biochemical characterization and localization 181
plasma contains sodium (abst) 773
processes in eccrine sweat gland 21:S-109
renal concentrating mechanism 21:S-43
sodium, L-carnitine effect on 754
targets of amiloride action 785
thyroid hormones 443
transepithelial proton, acidification 23:S-184
tumoral factors, in cancer, cAMP production and NaPiT (abst) 435
Tri-iodothyronine and renal transport 443
Trimethoprim-sulfamethoxazole, ADPKD 883
Tropical disease, renal changes (abst) 605
Tuberculous infection, uremics (abst) 607
Tubular
actions of AVP 21:S-76
Tubule
Bence Jones protein toxicity in proximal 850
cystic disease, viscoelastic properties in GBM 187
exchange systems, amiloride action 785
H^+ secretion in renal cortical 136
micropuncture localization of kallikrein secretion 26
procoagulant activity distribution 31
renal concentrating mechanism 21:S-43
Tubuloglomerular
feedback GFR, acute volume expansion, chloride 238
feedback in partial ureteral occlusion 212
hypertonic saline infustions in thoracic caval constriction 488
Tubulointerstitial nephritis
autoimmune, induction and characterization 642
Bence Jones protein toxicity 850
drug induced acute (abst) 612

Ultrafiltration
dialysate composition effect on fluid shift 267
peritoneal cavity lymphatic absorption in dialysis 165

peritoneal dialysis, lymphatics 219
Urea
appearance rate, diuretic-induced azotemia 47
Uremia
analysis of platelets (abst) 624
BCAA catabolism, acidosis, azotemia 808
carnitine metabolism in CRF 22:S-116
dialysis and exercise 876
epidemiology of idiopathic glomerular disease 112
erythrocyte insulin receptors 22:S-202
fasting, abnormal fatty acid utilization 22:S-145
gastrointestinal absorption of Al 821
hypercoagulable state (abst) 615
hypertonic hemodiafiltration management of 399
hypothalamus-pituitary-gonodal axis (abst) 620
insulin metabolism, ARF 22:S-109
insulin resistance, amino acid supply, protein 22:S-104
ketoacids, low protein diet, CRF progression 22:S-67
L-carnitine effect on sodium transport 754
lymphoblastogenesis (abst) 621
osteoclacin levels (abst) 622
parathyroidectomy, bone Al (abst) 620
phosphate, hyperphosphatemia prevention 22:S-215
proteases and other catabolic factors in RF 22:S-94
transplantation, calcium phosphate vitamin D (abst) 619
type I diabetes mellitus, glomerular epithelial cell 736
vitamin B-6 deficiency in azotemic rats 22:S-162
Uremic
branched-chain alpha ketoanalogs 22:S-186
cation transport in erythrocytes 256
circulating maltose, isomaltose in CRF 22:S-210
nitrogen intake, muscle protein synthesis 22:S-153
trombopathy (abst) 623
keto acid supplementation, bone metabolism 22:170
Urine
bacteruria prevalence in Ismailia (abst) 608
B2M significance in evaluation of renal function 635
concentrating mechanism, GFR and kidney mass 22:S-57
endopeptidase 24.11 in kinin metabolism 507
hemodialysis and hyperaluminemia 710
kallikrein secretion in rat nephron 26
mineralocorticoids (abst) 434
persistent azotemia, normal renal function 721
podocytic processes in immunologically mediated disorders 742
prostaglandin excretion, synthesis 1
renal stones, struvite 749
Urolithiasis
stone clinic effect (abst) 629

Valine, BCAA and acidosis in uremics 808
Valsalva maneuver, hypotension and HD 728
Vasoactive hormones, nephrotic syndrome 21:S-83
Vasodialation, ACE inhibition 78
Vasodialator, prostacyclin in ARF 479
Vasopressin
ADH secretion 21:S-20
aging effect on secretion, excretion and thirst 21:S-90
antagonists 21:S-76
biosynthesis, gene to peptide hormone 21:S-8
cellular events in action of 21:S-56
historical perspective of water metabolism 21:S-113
hyponatremia 21:S-67
membrane permeability, endocytosis 23:S-196
sensitive adenylate cyclase, target analysis, computer 23:S-43
signal transduction of G proteins 23:S-38
thirst and secretion of 21:S-14
Venous stenoses, vascular access grafts 395
Virus
tool to study polarity, membrane traffic, epithelial cell 23:S-201
Vitamin B-6
deficiency in azotemic rats 22:S-162
Vitamin D
calcium regulating hormones and the kidney 760
diminished PTH receptors in uremia 350
PTH axis, hypocalcemia 22:S-225
renal osteodystrophy 899
skeletal resistance to PTH 801
Volume
cellular handling of water 21:S-2
estimation of mean glomerular, diabetes 929
regulation in hot climate 21:S-97
saline expansion, tubuloglomerular feedback in occlusion 212
salt and hypertension 590

Water
aging effect on vasopressin action 21:S-90
cellular handling 21:S-2
hormonal regulation of metabolism, nephrotic children 21:S-83
loading, hemodynamics (abst) 776
metabolism, hyponatremia 21:S-67
metabolism in historical perspective 21:S-113
reverse osmosis, Al osteomalacia 96
Wegener's granulomatosis
autoantibodies (abst) 779
Wegener's granulomatosis (abst) 778
Wilson's disease, B2M 635

Zinc
seroconversion rate, hepatitis B vaccination 22:S-149
Zoonose, Hantavirus disease (abst) 774